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!
New!Mechanisms!of!Activation!by!Histone!Demethylases!in!Gene!Regulation!!Abstract!
!The! epigenetic!mechanisms! that! connect! hormone! signaling! to! chromatin! remain! largely!unknown.! Here! we! show! that! LSD1/KDM1A! is! a! critical! glucocorticoid! receptor! (GR)!coactivator! and! report! a! previously! unexplored! mechanism! where! LSD1! activates! gene!transcription!through!H3K4me2!demethylation.!We!demonstrate!that!direct!interaction!of!GR!with!LSD1!primarily!inhibit!its!activity!against!H3K4me1!in#vitro.!While!this!interaction!enables! GR! to! recruit! LSD1! in# vivo! and! allows! loss! of! H3K4me2,! it! impedes! further!demethylation.! Thus! resulting! in! conversion! of!H3K4me2! to!H3K4me1! at! enhancers! and!promotes!H3K27!acetylation!and!gene!activation.!We!also! find! that!H3K4me2! is!an!early!enhancer! mark! predicting! GR! and! LSD1! recruitment.! These! findings! differ! from! the!reported! mechanism! for! ER! and! ARSmediated! gene! activation,! providing! a! novel!mechanism!for!LSD1!coactivator!function!as!well!as!shed!light!on!the!role!of!H3K4me2!and!enhancers! in! hormoneSmediated! gene! regulation.! In! addition! we! present! evidence!supporting!never!before!characterized!H3K79me3!demethylase!activity!by!members!of!the!JMJD2!family!of!proteins.!!
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Chapter 1 
Introducing Epigenetics and Histone Methylation 
_________________________________________________________________________________________________            
 
The Far Reaching Umbrella of Epigenetics  Epigenetics is a newly emerged field with wide ranging impact on our understanding of biology. Epigenetics is generally accepted as the study of changes in gene expression or cellular phenotype that are not the result of changes in DNA sequence, some of which are heritable. The Greek root epi- implies mechanisms that occur on top of the genetic code, which also implies shared characteristics with classical genetics such as heritability. However, the origin of the word epigenetics has its true roots in an attempt to describe the connections between genetics and development in the late 1930’s by relating it to the word epigenesis 1. This lead to observations of a “new type of inheritance” occurring across mitotic cell divisions 2,3 and later across generations 4 being intermingled with studies of genetic “switches” responsible for turning genes on/off during development. These two lines of research have come together to form the modern epigenetic amalgamation, which encompasses processes as diverse as DNA methylation to nuclear architecture.     While there is good evidence supporting the existence of new non-genetic mechanisms of heritability, the mechanism(s) that transfer epigenetic information are not understood except in a few cases, such as for DNA methylation. On the other hand, our understanding of the molecular and biochemical switches that flip genes on and off has expanded dramatically since 1990’s. We now understand that myriad mechanisms, both nuclear and non-nuclear, affect the way genes are expressed, and most of these mechanisms have been 
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included under the umbrella of epigenetics. This helps explain the ambiguous definition of epigenetics as well as the debate in some circles about over whether inheritance is a requirement for the definition. While it remains to be determined whether heritable versus non-heritable changes in gene expression will eventually subdivide the field, one thing is certain; the epigenetic umbrella has many spokes all of which have proven biologically and clinically important.    Similar to discoveries of genetic mutations underlying disease, alteration of the epigenome has been similarly implicated in a wide variety of human diseases such as cancer, cognitive dysfunction, reproductive disorders, respiratory, autoimmune, and neurobehavioral diseases, as well as contributing to the aging process and evolution 5-12. Because epigenetics allows environmental signals to alter the function of the genome it is also thought to contribute heavily to diseases such as heart disease, obesity and diabetes, which we now understand to be complex mixtures of environmental/lifestyle exposures and genetic susceptibilities.  Epigenetic mechanisms allow the environment outside both the cell and the organism to influence gene expression. Environmental stimuli are detected and processed by an organism. In the case of multicellular organisms this signal is then transmitted to pertinent tissues and cell-types which respond in part by transmitting that signal to the nucleus where regulatory factors alter the pattern of gene expression. This allows an organism to respond to its environment down to the individual cell. An excellent example of this process is the human body’s response to stress.   
3  
 When a human encounters stress, the adrenal cortex releases hormones, one of which is cortisol. Cortisol is part of the glucocorticoid family of steroid hormones and circulates throughout the body to affect multiple organ systems. These effects include depressing the immune system and inflammation as well as mobilizing glucose. Cortisol carries out these effects in large part through binding to nuclear hormone receptors located in the cytoplasm of cells such as immune and liver cells. For example the glucocorticoid receptor (GR) is sequestered in the cytoplasm of many cell-types and upon binding to a ligand such as cortisol will translocate to the nucleus where it acts as a hormone-dependent transcription factor regulating specific gene targets 13. mRNA profiling of immune cells and hepatocytes responding to glucocorticoids reveals activation and suppression of genes involved in inflammatory signaling, glucose metabolism, and cell survival 14,15. These changes in gene expression of various cell and tissue types produce a coordinated response by the organism to the instigating stressor.    These processes are also critical during development where patterns of cell and tissue differentiation are directed by diffusible signaling molecules. Studies characterizing the epigenome throughout development have demonstrated significant alteration of the epigenetic landscape as cells specialize and thus restrict gene expression to a specific subset of genes 16,17. At various stages newly established epigenetic landscapes are maintained for many cellular generations and in some cases throughout the lifetime of the organism generating the foundation for cell and tissue differentiation.  
4  
However, unlike the long-term changes in the epigenome during development, similar mechanisms are also used on shorter time-scales. Returning to the example of stress, epigenetic switches temporarily alter gene expression allowing for dynamic adaptation to the environment. Most often, removal of the hormone signal will reset the switches allowing cells to revert to baseline function.  However, our understanding of the long-lasting effects of chronic exposure to altered physiological states and the contributions of stabile epigenetic changes are beginning to be explored 18,19. 
 
Chromatin Many epigenetic mechanisms center on the structure and function of the protein DNA complex known as chromatin. Even in its most unadorned state, the eukaryotic genome in nature is a complex structure of histone proteins wrapped in DNA, a single unit of which is called a nucleosome (Figure 1.1).  A nucleosome consists of an octamer of histone proteins (two of each H3, H4, H2A, H2B) wrapped in approximately 147 bp of DNA 20-23. Chromatin is a dynamic structure with two basic states known as euchromatin and heterochromatin. The two states are defined relative to each other with euchromatin being more loosely packaged allowing access to the DNA template, and heterochromatin being a more condensed structure with nucleosomes tightly packed together restricting access.   The most dramatic demonstration of these two states occurs during the cell cycle where the genome goes from a mixture of tightly and loosely packaged regions during interphase to the most extremely condensed state visible as individual chromosomes during mitosis.    
5  
At the level of the nucleosome there are several biochemical processes included under the umbrella of epigenetics.  Firstly, DNA itself can be chemically modified. In mammals the addition of a methyl group to the 5th position of cytosine was one of the first epigenetic marks to be discovered 24,25. Despite more than 65 years studying DNA methylation and the enzymes responsible for adding this modification, it is only in the last five years that we are beginning to understand how this mark is dynamically regulated. The recent discovery of DNA hydroxymethylases and subsequent modifications has shed new light on an old assumption about the long-term stability of DNA methylation 26.  Increasing evidence suggests DNA methylation, while perhaps not as dynamic as other chromatin modifications, is in fact reversible and actively regulated with significant implications for physiology and disease (reviewed in 27).    
Figure 1.1  Basic 3D structure of a single nucleosome.   DNA is represented by gray space-filling model and histone proteins are represented by blue ribbon models. Histone tails can be seen protruding from histone-DNA complex. 
(Image modified from James Hedberg original licensed under 
a Creative Commons Attribution-NonCommercial-ShareAlike 
3.0 Unported License.)  
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Up one level from DNA we find myriad post-translational modifications to histone proteins. The majority of these modifications occur on the N-terminal tail, which is an unstructured region of the histone protein protruding from the overall nucleosome structure (Figure 1.1). Many covalent modifications to histone tails have been described (acetylation, methylation, phosphorylation, sumolation, and ubiquitination) and tails can be modified at multiple amino acid residues allowing for numerous and diverse combinations.  Histone tails decorated with various marks signal information to the cell about the chromatin and transcriptional state of that region of the genome. Studies have also established that altering these covalent histone modifications directly and/or indirectly influences chromatin through the recruitment of effector proteins to specific chromatin regions 28-30. Similar to a system of color-coded tabs in your favorite book, histone modifications form a type of code on top of the genetic code indicating which regions and genes should be freely accessible and expressed and which regions should be silenced (as well as all manner of intermediate states).    While we have only begun to scratch the surface in understanding the histone code, some general trends have emerged. For example, histone acetylation is generally associated with euchromatin and gene activation. This in large part due to the additional negative charge added to the histone with this chemical modification (Figure 1.2 A). The increased negative charge helps repel the also negatively charged DNA opening chromatin up. However, other modifications such as methylation are less clear-cut. Methylation itself is neutral and therefore does not affect the biochemical properties of histone DNA interactions (Figure 1.2 B). Instead the impact of histone methylation on chromatin depends entirely on the 
7  
type of proteins that recognize this mark. Proteins that recognize specific modifications are called “readers” of the histone code. In terms of gene expression, the function of a histone reader depends on whether it possesses an enzymatic activity and/or recruits other proteins that favor open or closed chromatin. Decoding histone methylation has proven to be a daunting task. Methylation occurs at many residues (Figure 1.3), including one lysine in the globular region of the histone (H3K79), and to varying degrees with the addition of  
Figure 1.2  Lysine modifications.   (A) Histone lysine residues can be acetylated which changes the overall charge of the histone protein. (B) Histone lysine residues can also be methylated to three different degrees which does not change the charge of the protein.     
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 one, two or three methyl groups to a single residue (mono, di, or trimethylation) (Figure 1.2 B). Histone methylation has been implicated in euchromatin and heterochromatin formation as well as many stages of transcriptional regulation from initiation to mRNA processing all dependent on the residue and degree of methylation. Table 1.1 summarizes 
Figure 1.3  Histone tail modifications.   Crystal structure of a nucleosome with histones H2A shown in yellow, H2B in red, H3 in blue, and H4 in green. Tail residues are spelled out with known sites of methylation, acetylation and phosphorylation indicated.    
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the function of known methylation sites, but certainly represents an incomplete understanding of this modification. 
Table 1.1 Histone Methylation 
Histone Methylation Site Function H1 K26 Transcription silencing  H3 K4 Transcription activation   R8 Transcription silencing   K9 Transcription silencing or activation, imprinting, DNA methylation  
 R17 Transcription activation   K27 Transcription silencing, X-inactivation   K36 Transcription activation (elongation)   K79 Transcription activation (elongation), DNA repair/checkpoint response  H4 R3 Transcription activation  
 K20 Transcription silencing or activation, checkpoint response   K59 Transcription silencing    Just as there are readers of the histone code there are also “writers” and “erasers” of the code. These are enzymes responsible for regulating when and where histone modifications are laid down. The balance between writer and eraser activities dynamically regulates the histone code throughout processes such as development and cellular responses to stimuli. The writers and erasers for histone methylation are two classes of enzymes known as histone methyltransferases (HMTs, writers of histone methylation) and histone demethylases (HDMs, erasers of histone methylation). While the mechanisms of histone acetylation and deacetylation have been well studied for many years, the first HMT wasn’t 
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discovered until fairly recently 31 and up until the discovery of the first HDM (LSD1/KDM1a) three years later, histone methylation was thought to be an irreversible modification 32.   Following the discovery of LSD1, many more histone demethylases have been characterized solidifying histone methylation as a dynamic regulatory mechanism involving a balance between numerous writers and erasers. There are two major classes of histone demethylases. The first, so far only includes two proteins, LSD1 and LSD2, which carry out demethylation via a flavin dependent monamine oxidase reaction.  The second class mediates oxidative demethylation by radical attack catalyzed by a Jumonji C (JMJC) domain 33. While a large number of histone methyltransferases have been described, fewer of their counterpart demethylases have been identified. Until very recently no enzyme had been shown to demethylate arginine residues of histone tails 34, and some, such as methylation on histone H3 lysine 79 and H4 lysine 20 (H3K79 and H4K20), lack a characterized demethylases all together. This disparity leads many to believe there are novel histone demethylases left undiscovered along with no doubt many facets of the epigenetic code 35. Table 1.2 summarizes the known HDMs. Together DNA, histone, and nucleosome modification form an intricate and vastly unexplored network of interacting mechanisms that regulate chromatin structure and gene expression, both of which contribute significantly to the biology of major fields of research such as development and stem cells, as well as numerous human diseases and disorders 36.    
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Table 1.2 Histone demethylases  
HDM  Synonyms  Substrates  
LSD histone demethylases  LSD1 AOF2, BHC110, KDM1A  H3K4me1/2, H3K9me1/2  LSD2  AOF1, KDM1B  H3K4me1/2  
JMJC histone  demethylases  JMJD5  KDM8  H3K36me2  JMJD6 PSR, PTDSR  H3R2, H4R3  FBXL10 JHDM1B, KDM2B  H3K36me1/2/3  FBXL11 JHDM1A, KDM2A H3K36me1/2  KIAA1718 JHDM1D  H3K9me1/2, H3K27me1/2  PHF8 JHDM1F  H3K9me1/2, H4K20me1  PHF2  JHDM1E  H3K9me2  JMJD1A  JHDM2A, TSGA, KDM3A  H3K9me1/2  JMJD3  KDM6B H3K27me2/3  UTX  KDM6A H3K27me2/3 JMJD2A JHDM3A, KDM4A  H3K9me2/3, H3K36me2/3, H1.4K26me2/3 JMJD2B JHDM3B, KDM4B  H3K9me2/3, H3K36me2/3, H1.4K26me2/3 JMJD2C JHDM3C, GASC1, KDM4C  H3K9me2/3, H3K36me2/3, H1.4K26me2/3 JMJD2D JHDM3D, KDM4D  H3K9me2/3, H3K36me2/3, H1.4K26me2/3 JARID1A RBP2, KDM5A H3K4me2/3  JARID1B PLU1, KDM5B  H3K4me2/3  JARID1C SMCX, KDM5C H3K4me2/3  JARID1D SMCY, KDM5D H3K4me2/3  NO66  H3K4me2/3, H3K36me2/3   
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One appealing aspect of epigenetic research is the malleability of the epigenome through manipulation of protein and enzyme regulators. The advent of human genetics and advances in virology and recombinant DNA technologies has made the possibility of correcting genetic mutations that underlie human disease a plausible and auspicious goal.  Unfortunately, despite being first proposed over 40 years ago, gene therapy has been slow to break into the clinical setting as a safe and effective treatment. However, the paradigm shift in treatment strategy associated with gene therapy does not impede the development of epigenetic therapies given that enzymes are medical researchers’ favorite targets. Thus epigenetic therapies combine drugable targets with altering gene expression which have as significant an impact on physiology as direct mutation. In addition, the potential for long-lasting transmissibility of epimutations makes the epigenetic code an incredibly promising area of biomedical research.   
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Abstract The epigenetic mechanisms that connect hormone signaling to chromatin remain largely 
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unknown. Here we show that LSD1/KDM1A is a critical glucocorticoid receptor (GR) coactivator and report a previously unexplored mechanism where LSD1 activates gene transcription through H3K4me2 demethylation. We demonstrate that direct interaction of GR with LSD1 primarily inhibit its activity against H3K4me1 in vitro. While this interaction enables GR to recruit LSD1 in vivo and allows loss of H3K4me2, it impedes further demethylation. Thus resulting in conversion of H3K4me2 to H3K4me1 at enhancers and promotes H3K27 acetylation and gene activation. We also find that H3K4me2 is an early enhancer mark predicting GR and LSD1 recruitment. These findings differ from the reported mechanism for ER and AR-mediated gene activation, providing a novel mechanism for LSD1 coactivator function as well as shed light on the role of H3K4me2 and enhancers in hormone-mediated gene regulation.  
 
Background Glucocorticoids (GCs) are essential hormones (aka stress hormones) released from the adrenal cortex that affect many physiological processes. Cortisol, the natural GC in humans, is known to influence glucose and lipid metabolism, bone homeostasis, stress response, development, the immune system, as well as behavior. At the cellular level, GCs impact many processes including proliferation, apoptosis, and differentiation. Clinically, GC imbalance has been implicated in a wide-range of diseases while GC restraint on the immune system makes them some of the most potent treatments for inflammatory and immune diseases 1,2.    
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Many of the complex biological effects of GCs depend on activation of the glucocorticoid receptor (GR), a hormone inducible transcription factor 3. The GR is a class I nuclear receptor (NR) and a modular protein containing three distinct functional regions, a N-terminal activation domain (AD) containing a smaller defined activation function region (AF-1), a central DNA-binding domain, and a C-terminal ligand binding domain that can also contains a ligand-dependant AF region (AF-2) (Figure 2.1).  The mechanism of  
 
Figure 2.1 The Glucocorticoid receptor domain structure.  The N-terminal activation domain (AD) acts as a ligand independent activation domain interacting with other protein cofactors. DBD is the DNA binding domain separated from the ligand binding domain (LBD) by a hinge region (HR). AF-1 and AF-2 regions are critical for transcriptional activation of GR-regulated target genes. (Modified image from the Nuclear Receptor Resource http://nrresource.org)  
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transcriptional regulation by the GR has long been studied. Upon ligand exposure, the GC-bound GR complex translocates to the nucleus where it recognizes and binds directly to specific DNA sites called GR response elements (GREs). The GR can also bind DNA indirectly through a tethering mechanism involving protein-protein interactions with other transcription factors such as activating protein-1 (AP-1) and nuclear factor kappa B (NF-κB) (reviewed in 4). After binding DNA, GR can either activate or repress transcription depending on the integration of multiple factors 5. The net effect of GCs on an individual gene target depends upon other transcription factors present on both the target promoter and/or distal regulatory sites such as enhancers 6,7. Thus, understanding the full mechanism of GC action requires identifying not only the set of genes bound and regulated by the GR, but also the other transcription regulatory factors that may interact with the GR, and the disperse genomic loci where these interactions occur.  Covalent chromatin modifications to both histones and DNA have significant impacts on chromatin structure, function, and gene regulation, as well as emerging as important mechanisms in NR target gene regulation 8,9. NRs can affect chromatin by recruiting coactivator or corepressor proteins with chromatin or DNA modifying activities. For example, GR and many other NRs, recruit histone acetyltransferases (HATs) such as CBP, p300, p/CAF and SRC/p160, as well as ATP-dependent chromatin remodelers such as Swi/Snf proteins to initiate gene activation 10-13. The actions of these protein complexes, by addition of acetyl groups to histones and chromatin decondensation, allow basal transcription machinery and RNA PolII access to target genes 14-17. Conversely, corepressors such as histone deacetylases (HDAC) and NURD complexes recruited by NRs, 
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repress transcription by removal of acetylation and chromatin condensation 18. Together, the dynamics of histone acetylation and deacetylation offer a model for an epigenomic switch between on/off states of hormone target genes. However, the epigenome is extremely complex. Its regulation and associated gene activity is cell-type and gene specific, as well as requiring combinatorial histone codes and multi-layer mechanisms. Therefore, the current model of hormone-induced gene regulation is likely quite incomplete. For example, the most abundant and diverse histone modification in the epigenome is histone methylation. It has an incredibly complex impact on gene regulation, having been functionally linked to activation and repression depending on the genomic location, the methylated residue, or the degree of methylation (one, two, or three methyl groups). Similar to acetylation, histone methylation is regulated by a balance of apposing enzymes known as histone methyltransferases (HMTs) and histone demethylases (HDMs), which add or remove methyl groups, respectively.   The recent discovery of HDMs demonstrated the reversibility of histone methylation but also initiated the now rapid-pace characterization of histone demethylation in epigenetic transcriptional control. LSD1/KDM1A, the first identified histone demethylase, plays an essential role in a broad spectrum of biological processes, including gene regulation, stem cell differentiation, embryonic development, and tumorigenesis 19-22. Not surprisingly, LSD1’s mechanism of action in gene regulation (repression versus activation) is complex. LSD1 was originally characterized as a corepressor with in vitro validated demethylase activity against H3K4me1/2, an activity that can be regulated by associated protein such as CoREST and MTA 23,24. Soon after the discovery of its H3K4me1/2 demethylase activity, 
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LSD1 was also described as a H3K9 demethylase in the context of the hormone receptors ER and AR, offering one of the first examples of substrate specificity switching (K4me to K9me) by a HDM 25-30. However, this mechanism remains somewhat controversial given the lack of clear biochemical or structural support for how LSD1 changes substrate specificity to directly demethylate H3K9 31-33.   Transcriptional control by NRs through distal regulatory sites, such as enhancers, has been implicated as a key mechanism underlying hormone-mediated gene regulation 34-37. Recent work has begun to define distinctive histone modifications at enhancers that contribute to epigenetic control of enhancer activity. Heintzman et al. first defined an active enhancer chromatin signature as enriched in H3K4me1 and H3K27 acetylation (ac). While studies suggest H3K27ac is a key mark in the transition from inactive or poised enhancer states to fully active 38, growing evidence also supports a critical role for various H3K4 methyl states. H3K4me1 is the most generally accepted H3K4 feature of enhancers. However, H3K4me2 has been implicated as required for DNA binding of the ER and AR pioneer factor FoxA1 39. Lastly, a low level of H3K4me3 is also a hallmark of active enhancers distinguishing them from active transcription start sites (TSSs) 38,40. Thus, an enhancer-specific H3K4 methylation profile for all three methyl-states has been described.   Surprisingly, little is known about cellular, molecular, and biochemical mechanisms regulating changes in H3K4 methylation at enhancers. One study brought to light the importance of LSD1 in enhancer regulation in ESC differentiation where erasure of H3K4me1 by LSD1 at enhancers suppresses pluripotency transcriptional networks 19. 
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LSD1’s dual role in gene repression and activation as well as concerns about bona fide substrate switching by LSD1 leaves open the question of whether LSD1 is a direct H3K9 demethylase, and if not, what other mechanism(s) could account for its coactivator function in hormone-induced gene activation. The emerging roles of H3K4 methylation and LSD1 at gene enhancers as well as the importance of these sites in NR-mediated gene regulation raise the intriguing possibility that LSD1 could play a role in fine-tuning the methyl-states of its well-established substrate, H3K4, during the process of enhancer activation.   Potentially related to this dearth of knowledge surrounding regulation of H3K4 methylation at enhancers is the poorly understood cell-type specificity seen with NR function. GR in particular is the well known for a diversity of physiological effects. The ability of GCs to regulate such wide-ranging processes is in part due to tissue and cell-type specific affects. Transcriptomic analysis of GR action has revealed minimal overlap in GC-responsive expression profiles of different cell types 34,41,42.  One specific example that highlights this specificity well is the affect of GCs on cell survival. In lymphoid cell lineages such as T-cells and monocytes GCs induce apoptosis, contributing to immunosuppression and anti-inflammatory effects 43-45. However, in other cell types such as liver, osteoblasts, glioma, and lung carcinoma cells GCs have been found to inhibit apoptosis 46-51.   Genome-wide binding studies have also revealed that GR selectively targets a subset of GREs present in the genome 34,37,52-54. While there are a multitude of sites in the genome with sufficient sequence similarity to the GRE consensus motif, only a small fraction have 
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been found to be functional in terms of GR recruitment. In addition, DNase I hypersensitivity mapping, which is indicative of open versus closed chromatin states, has shown that the majority (~88%) of GR bound sites are kept in a constitutively accessible state 55. As the functions of epigenetic mechanisms are elucidated, a clear relationship between histone modification and chromatin state is being established. Together this strongly implicates histone modifiers in regulating a cell-type specific chromatin signature that is laid down prior to and independent of hormone exposure and that likely serves two functions. One is to establish a more permissive chromatin state (ie get target sites “primed and ready”) for GR induction; and two, to assist in targeting the GR complex to specific sites in the genome. However, the epigenetic modification and the proteins that regulate those modifications that underlie selective genomic targeting by the GR remains unknown and is a key question in understanding the versatile action of GCs in human physiology.  Here, using a GC-inducible model, we illustrate two new molecular mechanisms where LSD1 contributes to both GR-mediated target gene activation as well as suppression of non-functional GR targets by differentially controlling the H3K4me1/2 states at gene enhancers.  By microarray analysis we find that LSD1 is important for activation of most GC-responsive genes but also, that loss of LSD1 unmasks a large number of newly GC-responsive genes. As part of the GR complex LSD1 is recruited to many GR bound enhancer sites. Mechanistically, LSD1 H3K4 demethylase activity is crucial for changes in H3K4me1/2 and enhancer activation in response to GCs, challenging the dogma of LSD1 and NR-mediated gene activation via the elusive H3K9 demethylase activity. Contributing to this mechanism we find that GR modulates LSD1 HDM activity in vitro and in vivo by inhibiting removal of 
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H3K4me1 allowing this important enhancer mark to accumulate during activation. Additionally, we find that H3K4me2 is an important mark distinguishing functional GR binding sites prior to hormone exposure. Together these data support two roles for LSD1 in GR-mediated transcriptional regulation. One, in response to GCs GR-LSD1 interaction modulates LSD1 enzymatic activity to regulate the balance between H3K4me1 and me2 methyl-states at enhancers. And two, independent of GR, LSD1 and H3K4me2 contribute selective activation of a specific set of genes. 
 
Results 
LSD1 and GR form a stable complex dependent on the GR activation domain. To begin understanding the role of HDMs in GR-mediated gene regulation we tandem affinity purified (TAP) the GR-associated complex. A stable cell line expressing FLAG- and HA-tagged GR was generated in HeLa suspension cells. Cells were treated with the synthetic GR agonist Dexamethasone (DEX) prior to purification by FLAG and then HA immunoprecipitation. Silver staining of the FLAG and subsequent doubly purified HA sample along with a mock purification are shown in Figure 2.2 A, demonstrating high and specific enrichment. MS/MS analysis of the GR complex identified many proteins and complexes involved in chromatin modification/organization, gene transcription and regulation (Figure 2.2 D). Several key chromatin modifiers were enriched, including components of the Swi/Snf complex, the MLL2 H3K4 HMT complex, several HDACs, JMJD1C (a H3K9/36 HDM), and LSD1 (Figure 2.2 C). To confirm the stable interaction between LSD1 and GR, a third IP using LSD1 antibody was carried out from the HA TAP sample. The 
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reciprocal purification of GR subcomplexes containing LSD1 demonstrates the stable formation of the GR/LSD1 complex (Figure 2.2 B lane 2, and 2.2 C lanes 6 and 7).  GST pull-down assays using recombinant purified proteins were used to further characterize the LSD1-GR interaction. Several GR truncations were generated (Figure 2.3 A) to determine which region of the GR is most important for binding LSD1. Full length GST-GR pulled down His-LSD1 (Figure 2.3 B, lane 3) indicating the two proteins interact directly. The Gm1-419 truncation, but not Gm420-777, was also able to pulldown LSD1, suggesting the N-terminal activation domain (AD) is necessary and sufficient to bind LSD1. Additional AD truncations showed little binding activity suggesting no single smaller region within the AD is sufficient for strong binding to LSD1 (Figure 2.3 C).  
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Figure 2.2 LSD1 and GR form a stable complex.  
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LSD1 is recruited to endogenous GR binding sites and DEX-induced genes.  Given that LDS1 is part of the GR complex and directly interacts with GR, we next determined if LSD1 is recruited to endogenous GR binding sites in vivo. We preformed chromatin immunoprecipitation coupled with deep sequencing (ChIP-Seq) for GR and LSD1 after DEX or an ethanol vehicle (EtOH) treatment in the lung adenocarcinoma cell line, A549, which is an established model line for studying GR and GC action 34,41. In total,  
Figure 2.2 (Continued)  GR complex was tandem affinity purified (TAP) from stable cell lines expressing either HA-FLAG vector (Mock) or HA-FLAG-GR (GR). Silver staining of purified complexes shows numerous GR binding partners (A). A portion of the final HA purification was used for a third round of purification against LSD1 to isolate GR-LSD1 complexes (B). IP bait is indicated at the top of the gel, and the vector expressed in the cells above each lane.  Another portion of the HA purification was sent for MS/MS identification of co-purified proteins. GR associated proteins identified by MS/MS were analyzed and grouped based on published literature (D). Western blots confirmed many proteins identified by MS/MS in the GR and GR-LSD1 complexes (C). IP bait is indicated at the top of the blot, the vector expressed in the cells above each lane, and the antibody probe on the left. “GR*” was TAP against FLAG and then LSD1 to obtain GR-LSD1 complexes through only two purifications instead of three.  
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 1417 GR peaks were identified after DEX, and as expected, very little GR binding detected after EtOH. GR peaks were analyzed by the motif-calling program MEME, which returned the GRE consensus sequence suggesting the majority of binding sites contain GREs. Only a small percent (3.6%) of GR peaks were found within 2Kb of a known TSS (Figure 2.4 A), consistent with previous NR profiling 34,35. 
Figure 2.3 LSD1 and GR directly interact via the GR activation domain (AD) (1-419aa) in 
vitro.  Various GR truncations were generated (A) used for GST pulldown and demethylase assays. Silver stain of GST pulldown assays (B-C) showed HIS-LSD1 interacted with full length GR as well as the truncation (Gm1-419) containing the GR AD, but not Gm420-777 which lacks the AD, or further truncations of the AD.  
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 LSD1 ChIP-seq on the other hand showed binding throughout the genome in both the EtOH and DEX treated samples, suggesting a broad regulatory role in agreement with previous reports as well 30,56,57. Therefore, analysis of LSD1 binding focused on differential loci displaying DEX-dependent LSD1 binding (DDLB). These loci were defined as regions with ≥ 1.5-fold higher LSD1 signal density in the DEX sample compared to EtOH. The genome wide distribution of DDLB sites was very similar to GR with only 3.4% occurring at promoters (Figure 2.4 B). To address the question of LSD1 recruitment to GR binding sites, loci showing GR recruitment were compared to DDLB sites finding that 668 GR peaks (47%) showed ≥ 1.5-fold enrichment in LSD1 (Figure 2.4 C). Examples of GR and LSD1 profiles showing increased LSD1 binding at both GR bound regions as well as the TSSs of four DEX activated genes are shown in Figure 2.5.  
Figure 2.4 DEX-dependent LSD1 recruitment overlaps many endogenous GR binding sites.  ChIP-Seq against LSD1 and GR from A549 cells treated with ethanol (EtOH) or 100nM DEX (DEX) for 2 hours. Genomic distribution of DEX GR peaks (A) and the genomic distribution of DEX-dependant LSD1 binding (DDLB) (B) was very similar and primarily outside of promoters.  DDLB sites were defined as by LSD1 DEX/EtOH density ratio ≥ 1.5. Many GR peaks showed DEX-dependent increases in LSD1 binding demonstrated by the overlap between GR and DDLB peaks (C).  
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 To validate the genome-wide analysis, we employed ChIP-qPCR to examine GR (Figure 2.6 A) and LSD1 (Figure 2.6 B) at four DEX-activated genes with distal GR bound sites. DEX-induced genes lacking GR at the promoter were selected with the goal of better understanding potential enhancer functions. Specifically, per1 has well-characterized GRE and GR peak 2Kb upstream of the TSS (labeled 2kGRE). birc3 has a GR peak 12kb upstream of TSS (labeled 12kGB) and very close to a site identified previously 34. While to our knowledge GR binding sites or enhancers for cdkn1c or dusp1 have not been characterized our analysis identified the closest peaks at 105Kb downstream of the cdkn1c TSS (labeled 105kGB) within the body of a neighboring gene (KCNQ1, not regulated by DEX), and 1Kb upstream of the dusp1 TSS (labeled 1kGB). An intergenic region (interg) not bound by GR was used as a negative control. The results show significant DEX-dependent recruitment of LSD1 at GR peaks, validating the ChIP-Seq analysis. Moreover, for three of the four genes we also detect significant LSD1 enrichment at the TSS by qPCR. These results are consistent with the presence of LSD1 in the GR complex and strongly support a direct role for LSD1 in regulating GR targets gene activation.  
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Figure 2.5  Many GR binding sites as well as the promoters of DEX activated genes show DEX-dependent LSD1 recruitment.  
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Figure 2.6  ChIP-qPCR confirms DEX-dependent LSD1 recruitment to GR binding sites and promoters of DEX-activated genes.  ChIP against GR (A) or LSD1 (B) from A549 cells showed significant DEX-induced GR and LSD1 recruitment at four sites identified from ChIP-seq. Significant LSD1 recruitment was also observed at the promoters of each DEX-activated gene.    The average of 2-4 biological replicates are plotted ± standard error, p-values from two-tailed t-test.  
Figure 2.5  (Continued)  GR (red) and LSD1 (blue) ChIP-seq profiles from four DEX induced genes 
slc19a2 (A), zfp36 (B), birc3 (C), thbd (D), genes showed increased LSD1 binding after DEX at GR bound sites. In two examples GR binding is close to the TSS (slc19a2 and zfp36) while the other two genes show GR binding over 10Kb from the TSS (thbd and birc3). LSD1 recruitment is observed at both the distal GR binding sites and the TSS of birc3 (C) and thbd (D).  
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LSD1 is a key transcriptional coactivator of DEX-responsive genes and functionally 
linked to GC action. LSD1 has been shown to act as a coactivator for both ER and AR target genes. To begin addressing whether LSD1 is functionally associated with GR and playing a similar role, we compared global gene expression microarray analysis in A549 cells with or without LSD1 depletion. A lentiviral scramble (SC) control or LSD1-sepcific (L-sh1) shRNA was used to knockdown (KD) LSD1 expression. LSD1 KD was greater than 90% at the protein level and did not affect GR expression (Figure 2.7). Figure 2.8 A diagrams the analysis where DEX-regulated genes were identified by comparing control DEX and EtOH treated samples using a ≥ 2-fold cutoff. LSD1-dependent genes were identified by comparing the level of DEX regulation in L-sh1 to SC, using the formula (DEX/EtOH SC) / (DEX/EtOH L-sh1). Genes with >2-fold difference in activation or repression (i.e. 50% defect in the magnitude of activation or repression in L-sh1) were considered LSD1-dependent.   
 
 
Figure 2.7 LSD1 knockdown by lentiviral shRNA is efficient and does not significantly affect GR expression.  Lentiviral knockdown (KD) in A549 with either scramble control (SC), GFP control (GFP), or two different shRNA constructs against LSD1 (L-sh1, L-sh2) showed significant reductions in LSD1 mRNA (A) and protein (B), but no significant change in GR. The average of three biological replicates is plotted ± standard error, p-values from two-tailed t-test.   
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Figure 2.8 B shows heatmaps comparing mRNA levels after DEX or EtOH treatment in the SC control and L-sh1 samples.  225 genes were activated and 242 genes were repressed at least 2-fold by DEX in SC. 95 of the 225 activated genes (42%) showed at least a 50% defect in activation in the L-sh1 sample (Group B in Figure 2.8 B), and 123 of the 242 repressed genes (51%) showed at least a 50% defect in repression (Group D in Figure 2.8 B), suggesting that overall about 47% of DEX-regulated genes are LSD1-dependent. Genes in the heatmap are ranked from top to bottom by the ratio of DEX regulation in SC compared to L-sh1 for each group. Thus, the genes at the bottom of Group A or C show a mild defect in activation or repression but did not meet the 50% cut off for classification into the LSD1-dependent Group B or D.   Interestingly, 1,351 genes were also identified as DEX-regulated in the L-sh1 sample but not in the SC, 830 of which were up-regulated (Group E in Figure 2.8 B) and 521 were down-regulated (Group F in Figure 2.8 B). While some these genes appear to be only mildly DEX-regulated (i.e. activated or repressed less than 2-fold), and therefore were not included into Groups A-D, many of these genes do appear to be insensitive to DEX under control conditions. However, they become new DEX targets in the absence of LSD1; suggesting LSD1 is playing a role in repressing or masking these genes from DEX-regulation.   We hypothesized that these genes masked LSD1 are non-specific targets regulated by DEX in other cell types. To test this hypothesis we compared the genes in Groups E and F to DEX-induced expression profiles for four other cell types (3T3-L1 58, mouse liver cells 59, podocytes 60, and mouse C2C12 myotubes 61). We found that overall about 12% of the un-masked genes were DEX-regulated in at least one of the four other cell types, with 9.6% from Group E and 16.0% from Group F represented. GCs regulate gene expression in many cell types, very few of which have been experimentally profiled, and this overlap of newly DEX-responsive genes in the absence of LSD1 with previously characterized DEX-responsive genes might suggest a role for LSD1 in maintaining a cell-type specific GC response.  
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 Many of the DEX-regulated, LSD1-dependent targets were confirmed with a second shRNA (L-sh2) by RT-qPCR (Figure 2.9 A and C). To further validate LSD1 as a critical coactivator 
Figure 2.8   LSD1 is a critical transcriptional coactivator of DEX-responsive genes. Microarray analysis following lentiviral KD in A549 with either scramble control shRNA (SC) or LSD1 shRNA (L-sh1) was used to first identify DEX-regulated gene targets by at least a 2-fold change in mRNA, and second, identify LSD1-dependent targets defined by defective up or down regulation by at least 50% compared to SC (A). The heatmap display (B) of DEX and LSD1-regulated genes are grouped based on these criteria. Group A are 2-fold up-regulated in SC and up-regulated in L-sh1 to similar degree. Group B are also up-regulated by DEX 2-fold in SC, but the magnitude of activation after LSD1 KD is reduced by at least 50%, therefore we consider these gene to be DEX-induced and LSD1-dependent. Group C are 2-fold down-regulated in SC and to a similar degree in L-sh1. Group D are also 2-fold down-regulated in SC, but the magnitude of repression after LSD1 KD is reduced by at least 50%, therefore we consider these genes to be DEX-repressed and LSD1-dependent. Groups E and F do not meet the 2-fold cut off for DEX-regulation in SC, but are at least 2-fold up or down regulated in L-sh1.  All of the genes in the heatmap are ranked based on the ratio of DEX regulation in SC compared to L-sh1.   
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for GR, we used the MDA-kb2 cell line containing a stably integrated, DEX-inducible MMTV:Luciferase construct. LSD1 KD severely impaired DEX induced luciferase expression (Figure 2.9B).  
 
 
LSD1 coactivator function is important for DEX-mediated affects on proliferation, 
apoptosis, and adipogenesis. 
Figure 2.9  LSD1 knock down significantly impairs activation of many GC-target genes.  RT-qPCR confirmed many DEX-induced targets require LSD1 for full activation (A) in A549 cells and using a second LSD1 specific shRNA (L-sh2) (C). Similarly, a well-known GC-induced promoter, the MMTV driving a luciferase reporter gene, also required LSD1 for full DEX-activation (B). The average of 3-4 biological replicates is plotted ± standard error, p-values from two-tailed t-test.   
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If LSD1 is an important transcriptional co-regulator for GR, this role should translate downstream of transcription to impact the biological effects of GCs. To begin to understand which biological processes might be affected by LSD1 we used the DAVID functional annotation tool to carry out gene ontology analysis of DEX- induced and LSD1-regulated gene groups. The top p-value scores in both groups were negative regulators of apoptosis, consistent with previous reports of apoptosis suppression by DEX in A549 but also importantly implicating LSD1 as a key regulator of that suppression (Figure 2.10). Proliferation, another known DEX-regulated processes, was also significantly enriched as a top DEX-LSD1-regulated group (Figure 2.10 B, black bars). Interestingly, inflammation, a well-known DEX-regulated processes did not show up in the DEX-LSD1-regulated list (Figure 2.10 A, black bars). Together this analysis suggests LSD1 is important for specific sets of GC-regulated biological processes such as proliferation and survival, but may not play a critical role in others, such as inflammation.  To validate these top biological hits through functional studies we examined the role of LSD1 in GR-mediated affects on apoptosis and proliferation in A549. Indeed LSD1 is an important coregulator of DEX-mediated apoptosis and proliferation suppression as demonstrated by TUNEL and CCK8 cell viability assays (Figure 2.11). 
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Figure 2.10  LSD1 coactivator function for DEX-responsive genes is linked to GC biological action. GO analysis of DEX-induced genes from microarray. (A) Top 20 hits of DEX-induced genes ranked by p-value.  (B) Top 20 hits of DEX-induced and LSD1-dependent ranked by p-value. Black bars highlight categories of interest that are unique to either (A) or (B). 
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GCs also play important roles in development and cellular differentiation including adipogenesis. Stromal cells isolated from bone marrow (bMSC) and grown in tissue culture can be treated with a cocktail of signaling factors including DEX to promote differentiation into mature adipocytes. While an accurate chronology of all the steps involved in adipogenesis have yet to be elucidated growth arrest is known to be an early event followed by the expression of several key regulators including C/EBPβ, PPARγ, followed by C/EBPα leading to cellular remodeling and expression of many important adipocyte specific genes such as Leptin (reviewed in 62). The cell line A549 is derived from lung tissue and therefore lacks the ability to differentiate into adipocytes. However, two gene targets known to be involved in adipgenesis (CIDEC and C/EBPβ) were found to be regulated by GCs and LSD1 in our microarray, suggesting a possible role for LSD1 is GC-mediated adipogenesis.   To test this possibility mouse bMSCs were isolated from mice containing a LSD1 CRE cassette. Infection with a CRE containing adenovirus deleted the LSD1 gene. bMSCs were infected with either a CRE or EGFP control and grown in differentiation media containing for 14 days before fixation and Oil Red staining. RNA was harvested at day 0 (D0) and day 14 (D14) for RT-qPCR analysis. Oil Red staining at D14 showed many fewer cells with visible accumulation of lipid droplets in the CRE infected cells suggesting loss of LSD1 blocks adipogenesis (Figure 2.12 A). RT-qPCR analysis showed disrupted expression of several key adipogenic factors (Figure 2.12 B). Although, C/EBPβ was up regulated similarly in both EGFP and CRE infected cells, PPARγ and several proteins expressed in mature adipose were significantly reduced in the CRE sample. 
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Figure 2.11  LSD1 coactivator function is important for GC anti-apoptotic and anti-proliferative effects in A549. TUNEL staining was used to measure apoptosis in A549 treated with cisplatin (CIS). Cells treated with 0.5µM DEX with 50µM CIS were significantly resistant to apoptosis compared to co-treatment with EtOH, and KD of LSD1 abolished this resistance (A). CCK8 activity was used to measure proliferation in A549 treated with DEX for 5 days following KD with either a SC control, GR shRNA (GR-sh), LSD1 shRNA (L-sh1 or L-sh2), or LSD1 shRNA (L-sh2). The GR and LSD2 shRNAs were highly specific and did not affect LSD1 expression (B). DEX treatment significantly reduced proliferation (C and D, black line), and KD of GR or LSD1 rendered the cells resistant to proliferation inhibition while KD of LSD2 had no effect. TCP treatment to inhibit LSD1 activity also rendered cells resistant to DEX (D). The ratio of CCK8 activity in DEX vs. EtOH was calculated for each experiment. Average of 3-5 biological replicates is plotted for all, ± standard error, p-values from two-tailed t-test.  P-values for GR-sh, or either L-sh compared to SC in (C)  
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LSD1 does not significantly impact DEX inhibition of IL8 expression or release from 
A549 cells. GCs are well-known to inhibit inflammation and a simple example of this can be observed using A549 cells. Treatment with TNFα induces A549 cells to secrete the pro-inflammatory factor IL8, and co-treatment with DEX inhibits TNFα-induced IL8 release 63,64. Because anti-inflammatory affects are one of the most important clinical applications of GCs it was important to test LSD1’s role. We first examined IL8 mRNA levels by RT-qPCR and show that DEX treatment represses IL8 expression (Figure 2.13 A) and repression is unaffected by LSD1 KD (Figure 2.13 B). LSD1 and GR ChIP-seq data did not reveal any significant GR or LSD1 recruitment to the IL8 gene (data not shown), suggesting indirect repression in these cells.   DUSP1 is suggested to be an anti-inflammatory regulator downstream of GCs via inhibition of MAPK signaling 65-69. DUSP1 mRNA increases after DEX treatment (Figure 2.9 C) and was affected by LSD1 KD. Taken together LSD1 does not appear to play a role in regulating IL8 repression in response to DEX, but could potentially affect IL8 release indirectly through regulation of dusp1. Unable to predict the affect of LSD1 loss on IL8, secretion was measured directly by treating A549 cells with TNFα to induce secretion detected by ELISA on the media. Figure 2.13 B shows that treatment with DEX reduced the basal levels of IL8  
Figure 2.11 (Continued) and DMSO compared to TCP in (D) were ≥ 0.05 for all DEX concentrations. The average of 3-6 biological replicates are plotted ± standard error, p-values from two-tailed t-test.   
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Figure 2.12  LSD1 is important for bone marrow derived stromal cell (bMSC) adipogenesis. Stromal cells were isolated from CRE-LSD1 mice and infected with either a control (EGFP) or CRE containing virus to delete LSD1 (LSD1 KO).  Oil red staining of control and KO bMSCs after 14 days of growth in adipogenic differentiation media showed reduced lipid accumulation in the LSD1 KO cells (A). RT-qPCR expression analysis also showed defective up regulation of several key adipogenic regulators (B). The average of three qPCR replicates from one biological sample is plotted ± standard error.  
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 released as well as the TNFα-induced levels. KD of LSD1 did not affect DEX-inhibition of either the basal or TNFα-induced levels, suggesting LSD1 does not play a significant role in IL8 release in response to TNFα.  Together these data suggest that LSD1 plays a significant role in DEX-mediated gene regulation that translates from the level of transcription out to the cellular effects of DEX that result from those changes in gene expression.  
LSD1 HDM activity is critical for coactivation of DEX-responsive genes. LSD1 functions primary as is a histone demethylase, making its role in GR target gene regulation likely to involve this activity. Tranylcypromine (TCP) is an amine oxidase inhibitor used to inhibit LSD1 as well as LSD2, but does not inhibit JMJC HDMs. To examine the role of LSD1’s demethylase activity, DEX-induced luciferase activity in MDA Kb.2 cells (Figure 2.14), and mRNA levels of endogenous GR targets were measure following TCP treatment (Figure 2.15 A). Both DEX-induced luciferase activity and A549 gene expression 
Figure 2.13 LSD1 coactivator function for DEX-responsive genes is linked to GC biological action. (A) RT-qPCR of IL8 mRNA. (B) IL8 ELISA detecting IL8 secretion by A549 cells into growth media. Cells were treated with 2 ng/mL of TNFα for 24 hours after pretreatment for 6 hours with 100nM DEX (0.1 DEX) and/or viral shRNA for 5 days (dark gray bars are scramble, light gray are L-sh1). The average of three biological replicates is plotted ± standard error, p-values from two-tailed t-test.  
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were inhibited by TCP in a dose-dependent manner. To rule out a role for LSD2 as well as off-target effects of TCP, a rescue experiment was performed in A549. Cells were infect with lentivirus carrying a siRNA construct specific for wild-type LSD1 (Li), or vectors containing Li as well as the cDNA sequence for LSD1 with a silent mutation making it resistant to Li. This allows for KD of endogenous LSD1 and simultaneous rescue with the co-expressed LSD1 cDNA. Three different LSD1 cDNA constructs were used, wild-type LSD1 (WT), or two catalytically inactive mutants one with a mutation in the FAD domain (M1) and one with a mutation in the amine oxidase domain (M4). Expression levels of each construct as well as KD efficiency by Li are shown in Figure 2.15 B and C. Similar to L-sh1/2, Li prevented full DEX-induction (Figure 2.15 D), and co-expression of WT rescued this affect bringing expression similar to SC. M1 and M4 did not rescue leaving mRNA levels similar to Li demonstrating the necessity of LSD1 enzymatic activity for coactivator function. Together these experiments strongly support a critical role for LSD1 histone demethylase activity in gene activation by GCs.  
Figure 2.14 LSD1 enzymatic activity is critical for GC-induction of MMTV promoter.  The KDM1 inhibitor TCP antagonized DEX induction of the MMTV:Luciferase construct stably integrated in the MDA Kb.2 cell line. Average of three biological replicates is plotted ± standard error, p-values from two-tailed t-test.   
45  
DEX-induction differentially alters H3K4me1/2/3 at GR-target promoters and 
putative enhancers promoting activation. To understand the epigenetic mechanism underlying LSD1 coactivator function for GR, we first determine by ChIP-qPCR the status of several histone modifications on GR binding sites and target gene promoters before and after DEX treatment. H3K4me3, an epigenetic mark of gene activation, increased significantly at the TSS of all four genes (per1, cdkn1c, 
birc3, dusp1) as expected for DEX-induction (Figure 2.16 A). While H3K4me2 is also generally considered an activating mark, we surprisingly observed decreased levels at the TSS of all four genes (Figure 2.16 B). In contrast to the dramatic changes in H3K4me2/3, H3K4me1, a recently defined enhancer mark, showed no significant change at the TSS (Figure 2.16 C).  However, this DEX-induced H3K4 profile at the TSS differed from GR bound putative enhancer sites (herein referred to as GB enhancers). Three of the four GB enhancers showed relatively high H3K4me2 levels prior to DEX which, similar to the TSS, decreased upon induction (Figure 2.16 B). Distinct from the TSS, this decrease coincided with a significant increase in H3K4me1 (Figure 2.16 C) while H3K4me3 was depleted and remained so after DEX (Figure 2.16 A). The H3K4me1/3 profile at GBs is consistent with enhancer function, and further supported by observed DEX-induced increases in H3K27ac (Figure 2.16 D) another established mark of active enhancers.  
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Figure 2.15  LSD1 is a critical transcriptional coactivator of DEX-responsive genes depending on its demethylase activity. (A) RT-qPCR of several microarray indentified DEX-induced, LSD1-dependent genes after similar TCP treatment in A549. (B) RT-qPCR of LSD1 mRNA after lentiviral infection containing a LSD1 RNAi construct (Li), or Li with cDNA constructs on the same plasmid for wild type LSD1 (WT) or two catalytic mutants (M1 or M4). Average of 3-4 biological replicates is plotted ± standard error, p-values from two-tailed t-test.  
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Given LSD1’s proposed role as a H3K9 demethylase in ER and AR target gene activation we also examined the levels H3K9me2 (Figure 2.16 E), and found most sites both GB enhancers and the TSS did not show significant changes in H3K9me2 after DEX. Two exceptions were the GB nearest birc3 and the TSS of dusp1 which both showed a DEX-induced decrease in H3K9me2. Most other sites examined showed low levels of H3K9me2 relative to the intergenic control suggesting that this mark is low prior to hormone treatment and therefore unlikely to be further reduced and may therefore not play a major role in regulating these gene targets. The observation of H3K9me2 loss at the birc3 GB enhancer may indicate that a subset of GB enhancers are more significantly silenced prior to hormone exposure 39. Taken together the data shows a shift in the H3K4 methylation profile away from me2 and toward me3 at the TSS and toward me1 at GBs enhancers, with only minor contributions from H3K9me2 loss.  To validate observed changes in H3K4me2/1 as a general phenomenon, we examined genome-wide changes by ChIP-Seq. H3K4me1 density measured across all GR peaks and averaged showed a significant increase after DEX (Figure 2.17 A, p=1.21623e-16 calculated from 2-tailed t-test of densities summed across GR peaks), whereas H3K4me2 showed a significant decrease (Figure 2.17 B, p=1.92442e-5 calculated from 2-tailed t-test of densities summed across GR peaks). Similar to the qPCR results, global analysis show that H3K4me2 levels also decreased at the promoters of genes identified by microarray as DEX-induced and LSD1-dependant, while H3K4me1 remained low (Figure 2.17 C). Taken together the data confirms a trend shifting the H3K4 methylation profile away from me2, and toward me3 at the TSS, and toward me1 at GB enhancers.  
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Figure 2.16 DEX-induction changes the H3K4 methylation profile at both enhancers and promoters. 
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 Strikingly, this analysis also suggests that a high level of H3K4me2 at GR binding sites prior to DEX induction is a prominent epigenetic feature of LSD1-occupied GBs. To better understand the relationship between H3K4me1/2 prior to GR/LSD1 recruitment, a heatmap of LSD1 density on GR peaks after DEX was compared to heatmaps of H3K4me1 
Figure 2.17 Genome-wide analysis confirms trends in H3K4me2/1. 
The density of H3K4me1 and me 2 were averaged over all GR ChIP-Seq peaks showing 
a trend toward increased H3K4me1 (A) and decreased H3K4me2 (B). Loss of H3K4me2 
was also observed around the TSS of genes that are DEX-induced and LSD1-dependent 
as identified microarray.    
Figure 2.16 (Continued) 100nM DEX treatment for two hours resulted in significant increases in H3K4me3 at the TSS of four DEX-induced genes (A). H3K4me2 levels were significantly reduced at GR bound putative enhancers (GB enhancers) and TSSs (B), and H3K4me1 was significantly increased at GB enhancers (C). H3K27ac was also increased at GB enhancers (D), while H3K9me2 showed mostly low and unchanging levels (E).  Average of 2-6 biological replicates is plotted ± standard error, p-values from two-tailed t-test.  
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and me2 after EtOH treatment, which is representative of the levels prior to DEX (Figure 2.18 A). Loci were ranked by LSD1 density from high to low (top to bottom) revealing a markedly similar pattern in H3K4me2 of high to low density, and a similar but less distinct pattern for H3K4me1. To measure the correlation between LSD1 and H3K4me2, average densities were plotted generating a Pearson correlation coefficient of 0.4587 (Figure 2.18 B). These analyses suggest LSD1 is preferentially targeted to GBs with preexisting high levels H3K4me2. Subsequent H3K4me1 and H3K27ac enrichment (Figure 2.16 C and D) suggests H3K4me2 at GBs may be an important early epigenetic signal distinguishing enhancers ready to be converted to more activate states.  
 
Figure 2.18  H3K4me2 is enriched at functional GR binding sites prior to GR and LSD1 recruitment. 
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 This led us to question whether H3K4me2 could be a distinguishing mark of functional enhancers prior to activation. Both enhancers and NR binding sites are known to be highly cell-type specific, making predictions of functionality based solely on DNA sequence difficult. To investigate the relationship between H3K4me1/2 and functional regulatory sites, as defined by GR binding, we compared our GR ChIP-Seq in A549 to another cell type. GR binding sites in LNCaP cells were obtained from a publicly available dataset 70 and compared to A549. LNCaP-specific sites were identified by excluding sites bound by GR in both cell lines. These LNCaP-specific sites represent potential GR binding sites given the demonstrated capacity to recruit GR in LNCaP cells, but which we consider non-functional in A549 due to the lack of GR binding in our ChIP-Seq. Once non-functional GR binding sites were identified we compared the levels of H3K4me1/2 at function versus non-functional sites in the A549 EtOH sample (Figure 2.18 C). Quantifying each mark prior to DEX-induction revealed that H3K4me2 was much higher (2.4-fold) at functional GR binding sites compared to non-functional sites prior to DEX, while H3K4me1 was only 1.5-fold higher. 
Figure 2.18  (Continued) Heatmaps of GR and LSD1 binding after DEX, and H3K4me1 and me2 prior to DEX (EtOH) showed a correlation between LSD1 binding after DEX and H3K4me2 levels prior to DEX (A). Plotting the density on GR peaks of LSD1 after DEX and H3K4me2 before DEX showed a Pearson correlation coefficient of 0.4587 (B). GR ChIP-Seq data from A549 was compared to published data in LNCaP cells. GR binding sites unique to LNCaP cells were considered LNCaP specific. The density of H3K4me2 and H3K4me1 was averaged on GR peaks from A549 (A549 function) and compared to LNCaP specific sites showing higher levels of H3K4me2 at functional versus non-functional sites (C).  
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The greater enrichment of H3K4me2 over H3K4me1 prior to stimulation suggests H3K4me2 is a more prominent marker pre-determining GR binding and supporting a role as an early enhancer mark. These studies support a significant role for H3K4 methylation in GR-mediated target gene activation and raise a critical question as to how the H3K4 methyl code is regulated and the potential role of GR, LSD1, and their interactions in that regulation. 
 
GR inhibits LSD1 H3K4, in particular H3K4me1, demethylase activity in vitro. To investigate the enzymatic nature of LSD1 in GR-mediated gene activation, we examine the demethylase activity of the purified GR complex using assay conditions favoring FAD dependent histone demethylation 71. Surprisingly, unlike previously reported androgen receptor (AR) containing LSD1 complexes showing H3K9me2 demethylase activity 25,26,28, the GR complex containing LSD1 showed no detectible HDM activity against H3K4 or H3K9, suggesting inhibition by a factor(s) in the complex (Figure 2.19 A). Given the direct interaction between GR and LSD1 (Figure 2.3 B), we hypothesized that GR was a likely candidate and used an in vitro biochemical approach to test this possibility.  Purified recombinant GR was added to demethylase assays to determine the affect on LSD1 activity. Increasing amounts of GR inhibit LSD1 demethylation of H3K4me1/2 (Figure 2.19 B). This affect was ligand independent (Figure 2.19 B, lane 4) consistent with the finding that LSD1 and GR interact independent of the ligand-binding domain (Figure 2.3 B). DEX in the presence of boiled GR or GST protein had no effect (Figure 2.19 B, lanes 5 and 6). Again unlike the effect of AR or ER on LSD1 activity, no appreciable H3K9me2 demethylation was 
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detected under any conditions, suggesting that LSD1 was not functioning as a coactivator through direct H3K9 demethylation in the GR complex. Similar inhibitory effects of GR on LSD1 H3K4 demethylase activity were obtained in nucleosome assays which contain CoREST, an LSD1 cofactor required for efficient demethylation of nucleosomes, a more physiologically relevant LSD1 substrate (Figure 2.19 C). GR truncations were again used to test which domain of GR is responsible for inhibiting LSD1 (Figure 2.3 A). Consistent with the GST pulldowns, the AD (1-419aa) was required and sufficient for effective inhibition (Figure 2.19 D).   To assess the affect of GR on LSD1 substrate specificity, densitometry quantification of multiple experiments was used to calculate the fold inhibition on each mark. Inhibition of LSD1 activity against H3K4me2 nucleosomes was modest while inhibition of H3K4me1 loss was significantly stronger (Figure 2.19 E). A similar trend was observed with stronger inhibition of H3K4me1 over me2 demethylation on histone substrates and with GR truncations (Figure 2.19 F). Together these data provide an in vitro biochemical explanation for the decrease of H3K4me2 and concurrent accumulation of H3K4me1 at sites co-occupied by LSD1 and GR.  
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Figure 2.19  GR inhibits LSD1 H3K4, in particular H3K4me1, demethylase activity in vitro. 
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NR limiting of LSD1 H3K4 demethylase activity is likely a general phenomenon and 
novel epigenetic mechanism underlying NR-mediated gene regulation. Given that LSD1 plays a role in both ER and AR target gene activation, it is possible that regulation of LSD1 H3K4 demethylase activity is an aspect of LSD1 coactivator function for NRs generally. To determine whether or not LSD1 inhibition is unique to GR, several other nuclear receptors were tested in LSD1 HDM assays. Figure 2.20 B shows western blots of HDM assays for estrogen receptor (ER), androgen receptor (AR), a mineralocorticoid receptor N-terminal truncation (MR 1-110aa), thyroid receptor (TR), retinoic acid receptor (RAR), retinoic X receptor (RXR), and RAR-related orphan receptor β (RORβ). All proteins tested except RORβ showed some inhibition of LSD1 activity. Interestingly RORβ lacks a classic N-terminal activation domain (Figure 2.20 A), which may explain the lack of inhibition. These data support a conserved function for NR proteins and specifically the N-terminal activation domain of NRs in inhibiting the H3K4 demethylase activity of LSD1. 
Figure 2.19  (Continued) Modification specific antibodies were used for Western Blotting to detect enzymatic activity in various assays. Testing the GR TAP complex showed no detectible HDM activity against H3K4 or H3K9, but deacetylation of histones was detected (A). Purified recombinant GR added to LSD1 demethylases of histones inhibited demethylation of H3K4me1/2 (B). GR truncations (Figure 2.3 A) containing the activation also inhibited LSD1 demethylase activity (C) and inhibition of LSD1 was not limited to histones but also occurred when nucleosomes and coREST were used (D). No demethylation of H3K9me2 was detected. Densitometry of demethylase assay Western Blots showed that GR and the GR AD inhibit demethylation of H3K4me1 preferentially over H3K4me2 nucleosomes (E) and histones (F). The average of 3-6 biological replicates is plotted ± standard error, p-values from two-tailed t-test.   
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  From this we conclude that GR, and more specifically the AD, regulates LSD1 activity by preferentially inhibiting LSD1 H3K4me1 demethylation in vitro. This is consistent with our 
in vivo finding that regions bound by both LSD1 and GR show loss of H3K4me2 but accumulation of H3K4me1, while regions without GR (TSSs) show loss of H3K4me2 but no 
Figure 2.20  Many nuclear receptors inhibit LSD1 H3K4 demethylase activity 
in vitro. A diagram of the activation domains of NRs tests shows wide variety in structures (A). Multiple NRs inhibit LSD1 demethylase activity when added to 
in vitro histone demethylase assays (B). Inhibition correlates with the presence of an activation domain.  
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H3K4me1 accumulation. From this we hypothesize that H3K4me2 loss and H3K4me1 accumulation in vivo are dependent on GR-regulated LSD1 activity. 
 
LSD1 is required for changes in H3K4me1/2 and enhancer activation. To test the above hypothesis, we first examine whether LSD1 activity is responsible for H3K4me2 loss and selective H3K4me1 increases using LSD1 KD of TCP and ChIP-qPCR profiling of H3K4me1/2/3 on the previously defined genes. Neither LSD1 KD nor inhibition of HDM activity prevented GR binding suggesting GR recruitment is independent of LSD1 (Figure 2.21 A) and consistent with RT-qPCR data showing impaired by not fully suppressed activation (Figure 2.9 C). 
 Also consistent is the finding that H3K4me3 trended toward higher levels and remained restricted primarily to the TSS after DEX treatment similar to controls (Figure 2.21 B), suggesting the addition of this mark is also LSD1-independent. However, changes in H3K4me2/1 and H3K27ac were dependent on LSD1 and its activity. After LSD1 KD no change was observed in H3K4me2 at the TSS or GB enhancers and interestingly, TCP treatment caused increased H3K4me2 levels at both GB enhancers and the TSS (Figure 2.22 A),suggesting LSD1 activity is critical to keep this mark low after DEX-induction. H3K4me1 levels failed to increase at GB enhancers in both KD and TCP cells, while the TSS remained low and unchanged (Figure 2.22 B). Similar to H3K4me1, H3K27ac also failed to increase at GB enhancers suggesting loss of LSD1 or inhibition of its activity disrupts enhancer activation (Figure 2.23).  
58  
Figure 2.21  GR chromatin binding and H3K4me3 is not disrupted by loss of LSD1 activity. 
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  H3K9me2 levels were also examined and found to be disrupted after LSD1 KD or inhibition by TCP. The two sites that showed loss of H3K9me2 in response to DEX no longer decreased and several sites showed an increase in H3K9me2 levels (Figure 2.24) similar to what was observed for H3K4me2 (Figure 2.22 A).  This confirms previous findings that LSD1 is required for loss of H3K9me2 in response to hormone-induced gene activation. However, it also supports also supports a possible interdependence between H3K4me2 and H3K9me2.   
Figure 2.21  (Continued) ChIP-qPCR against GR from A549 cells treated with either LSD1 shRNA (L-sh1) or TCP showed DEX-induced GR recruitment independent of LSD1 (A). ChIP-qPCR against H3K4me3 showed trends toward increased levels after DEX treatment (B). Average of 2-3 biological replicates is plotted ± standard error, p-values from two-tailed t-test.  
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Figure 2.22  LSD1 is a key factor responsible for direct changes in H3K4me1/2. 
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Figure 2.23 LSD1 is a key factor responsible for enhancer activation. ChIP-qPCR against H3K27ac from A549 cells treated with either LSD1 shRNA (L-sh1) or TCP no longer showed increased levels of the active enhancer mark, H3K27ac, after DEX treatment. Average of 2-4 biological replicates is plotted ± standard error, p-values from two-tailed t-test.  
Figure 2.22  (Continued) ChIP-qPCR against H3K4me2 (A) or H3K4me1 (B) from A549 cells treated with either LSD1 shRNA (L-sh1) or TCP no longer showed DEX-induced decreases in H3K4me2 or increases in H3K4me1. Average of 2-4 biological replicates is plotted ± standard error, p-values from two-tailed t-test. 
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Discussion Previous work has showed that LSD1 is an important coactivator for AR and ER gene targets 25-30. We show here that LSD1 is also an important coactivator for GR, suggesting it may be a general NR coactivator. Combining all of these mechanistic elements we envision 
Figure 2.24 LSD1 is a key factor responsible for enhancer activation. ChIP-qPCR against H3K9me2 from A549 cells treated with either LSD1 shRNA (L-sh1) or TCP no longer showed decreased levels of H3K9me2 after DEX treatment, and a general trend toward increased levels were seen at several other sites. Average of 2-5 biological replicates is plotted ± standard error, p-values from two-tailed t-test.  
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LSD1’s role in GR target gene regulation as follows. In the absence of hormone LSD1 is bound to a certain subset of non-specific GREs and possibly removing H3K4me2/1 to mask these sites from future GR activation. Upon hormone exposure and GR translocation to the nucleus LSD1 and GR interact. The methods employed here do not allow us to precisely delineate the timing and location of LSD1 and GR first interaction. We find modest levels of LSD1 at GR bound sites prior to GR binding as well as moderate increases in LSD1 levels upon GR binding. From this data it is impossible to know whether GR can interact with and regulate LSD1 already bound to chromatin or if GR forms a complex with LSD1 prior to chromatin binding and evicts previously bound LSD1 exchanging it for new LSD1 containing complexes. Given the highly dynamic nature of GR DNA binding, it is likely that the true mechanism is somewhere in between these two discrete mechanisms. LSD1 association with DNA may also be highly dynamic and frequent flux between bound and unbound states may provide opportunities for interaction with GR and quick re-association with chromatin.   The role of LSD1 at functional GREs, albeit at low levels, prior to GR binding remains mysterious given our finding of high levels of H3K4me2/1 at these sites. Perhaps this is indicative of LSD1 recruitment to GREs generally, and the presence of other factors determines the functionality of the GRE by regulating LSD1 activity to ultimately mask or tag the GRE for activation. GR is not alone in its ability to regulate LSD1 activity. CoREST facilitates LSD1-mediated demethylation of nucleosomes while BHC80 has been found to inhibit LSD1 activity in vitro 24.   
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LSD1 has been identified in many complexes 20,57,72-78, suggesting that it may be a widely utilized epigenetic tool distributed throughout the genome for various purposes.  Perhaps, the key regulatory point for LSD1 is not localization, but instead through specific binding partners with varying abilities to regulate LSD1 activity.  For example, unencumbered LSD1 bound to a nonfunctional GRE would remove H3K4me1/2 while LSD1 bound to a functional GRE in complex with a full inhibitor would allow H3K4me1/2 accumulation prior to GR activation. Swapping of the full inhibitor for GR would then allow removal of H3K4me2 by LSD1 and further accumulation of H3K4me1 through conversion from H3K4me2. Swapping sequence specific regulators such as GR while minimizing the changes required of chromatin the tool-kit may provide an advantage for highly dynamic systems such as hormone responses.   Regardless of the exact timing/location, association of LSD1 and GR at a chromatin site results in partial inhibition of LSD1 activity converting the early poised enhancer H3K4me2 mark to H3K4me1 and facilitating further enhancer activation likely through recruitment of other proteins, including an H3K27 acetyltransferase such as CBP/P300. Full enhancer activation then leads to chromatin looping bringing transcription factor complexes in proximity of the promoter and TSS recruiting basal transcription machinery and turning the gene on. Thus LSD1’s role in GR target gene regulation occurs at the early stages of target discrimination and enhancer activation. 
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Figure 2.25  Model of LSD1’s role in activation of H3K4me2 marked enhancers.  Pioneer factor(s) may be responsible for recognizing and/or protecting specific enhancer sites prior to GC exposure and helping recruit GR after hormone exposure similar to findings with FOXA1 and ER. Once GR and LSD1 are co-localized the H3K4me2 enhancer signature is converted to H3K4me1 by partially inhibited LSD1 and the enhancer is activated with additional modifications such H3K27ac likely laid down by HATs such as p300 found in the GR TAP complex.  At promoters recruited LSD1 in the absences of GR removes H3K4me2 and me1. The recruitment of H3K4 HMTs such as MLL2 found in the GR TAP complex counterbalance LSD1 activity to generate a region around the TSS of high H3K4me3 (protected from LSD1 activity) but lacking intermediate states of methylation (A). Microarray data implicates LSD1 silencing non-specific GR targets, and we propose a possible mechanism where LSD1 removes the H3K4me2 enhancer signature helping pre-establish a specific H3K4me2 profile throughout the genome that will allow for cell-type 
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 Importantly, our work introduces two new epigenetic mechanisms involving LSD1 to the model of GC target gene regulation (Figure 2.25). First is the role of LSD1 in establishing an active enhancer histone code for GC inducible genes as well as maintaining low H3K4me1/2 at the TSS after activation. We propose that GR recruitment and H3K4me3 methylation are independent or prior to LSD1 function, whereas H3K4me1 accumulation is the result of converting H3K4me2 to me1 via precise control of LSD1 activity by GR. To uncover the molecular and biochemical mechanism underlying GR regulation of LSD1 we demonstrate a direct protein-protein interaction between GR and LSD1 and identify the activation domain of GR (1-419aa) as the critical region for interacting and regulating LSD1 
in vitro. Importantly, we show that direct interaction with GR preferentially inhibits LSD1 H3K4me1 demethylase activity. To our knowledge, this study is the first to report a molecular mechanism by which LSD1 acting as a H3K4 HDM participates in gene activation.  LSD1-dependent enrichment of H3K4me1 and H3K27ac at distal GBs strongly supports epigenetic regulation at enhancers by GR/LSD1 complexes. Hormone-inducible enhancers/genes are thought to be in a type of poised state prior to ligand activation 55,79. H3K4me2 has been shown to be critical for binding of the NR recruiting, pioneer factor, FoxA1 39, suggesting this mark may be important for early recognition of functional NR binding sites perhaps in an early poised state. Interestingly, loss of FoxA1 results in 
Figure 2.25 (Continued) establish a specific H3K4me2 profile throughout the genome that will allow for cell-type specific GR targeting (B). 
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reduced H3K4me1 at many enhancers 80, which supports the role of H3K4me1 in enhancer function but also supports a role for H3K4me2 and pioneer factors upstream of H3K4me1. The present study shows that H3K4me2 was more highly enriched than H3K4me1 at functional GBs prior to GC stimulation. The observed correlation between   LSD1 binding and H3K4me2, as well as the LSD1-dependent drop in H3K4me2 after DEX suggests LSD1 is targeted to its substrate, which is acting as an early mark of inducible enhancers (Figure 2.25A). While studies in ES cells show that H3K4me1 is a mark of poised enhancers that transition to an active state with H3K27ac and p300 binding 38, our study does not distinguish an H3K4me1-only state from one with both H3K4me1 and H3K27ac. This may be due to the rapid nature of DEX induction, unlike the stepwise process of cellular differentiation. We propose the H3K4me2, more so than H3K4me1, represents an early poised state, and/or a poised state unique to rapidly inducible gene systems and that high levels of H3K4me2 precede changes in H3K4me1 and activation. We find that cooperative control of the swift transition from H3K4me2 to H3K4me1 by GR/LSD1 complexes is a prerequisite to initiate enhancer activation.   While we find that H3K27ac is dependent on LSD1 activity (Figure 2.23) it is unlikely that LSD1 is directly responsible, but instead that this mark is dependent on H3K4me1 accumulation. This is consistent with the characterization of H3K27ac as a mark that follows H3K4me1 during ESC differentiation 38. However, given the associated loss of H3K4me2, the simplest explanation for H3K4me1 accumulation is as a direct result of LSD1-mediated removal of one methyl group. The findings that H3K4me1 only accumulates 
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on LSD1 bound sites also bound by GR, and that GR inhibits LSD1-mediated demethylation of H3K4me1 in vitro support a mechanism where GR partially inhibits LSD1 activity allowing conversion of H3K4me2 to H3K4me1. Another possible explanation for H3K4me1 accumulation not addressed by this study is the recruitment of an H3K4 methyltransferase to GB enhancers. In Drosophila MLL3/4 was shown to specifically mono-methylate H3K4 at enhancers and MLL2 was identified in our GR complex (Figure 2.2 C). While it is possible that an MLL complex recruited by GR to enhancers is also involved in H3K4me1 accumulation, the dependence of this mark on LSD1 would suggest at the very least cooperation between HMT and HDM activities. However, in such a mechanism we would predict that loss of LSD1 would disrupt the balance between HMT/HDM driving H3K4me2/3 levels up at GB enhancers, which was not observed after LSD1 KD (Figure 2.21 B and 2.22 A). Taking these data together we propose a molecular model where LSD1 is recruited to sites with high H3K4me2, and at sites also bound by GR, LSD1 is partially inhibited converting some H3K4me2 to H3K4me1 and thus promoting H3K27 acetylation and enhancer activation.   Induction of LSD1 binding at the TSS of DEX-regulated genes and the loss of H3K4me2 at these sites suggest a contribution to the mechanism of gene activation. Although H3K4me2 is generally associated with activation and thus its loss should contribute to silencing, its role may be more nuanced. In yeast, H3K4me2 has been implicated as a type of memory mark of recent transcription at the promoters of inducible genes, which needs to be removed for full reactivation 81. This mechanism may relate to the methods employed in this study, where cells were grown in normal serum containing many hormones prior to 
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growth in stripped serum for 16-24 hours and then reintroduction of an activating signal by DEX. The high levels of H3K4me2 at the TSS may be a type of memory mark of previous expression in normal serum. A second explanation might involve conversion of H3K4me2 to me3, likely due to recruitment of an HMT complex such as MLL2 to the TSS. Again LSD1 may play a role in counterbalancing HMT activity at the TSS to generate a region that is primarily trimethylated. This is supported by the observation that H3K4me2 levels increase along with H3K4me3 after TCP treatment suggesting LSD1 helps maintain low levels of H3K4me2 while H3K4me3 accumulates. While HMT and HDM activities are typically thought of as functionally counteracting one another, i.e. K4 demethylation as repressive and K4 methylation as activating, these opposing reactions could also be combined to generate highly specific methyl states. For example, LSD1 can only remove H3K4me1/2 but not me3. Therefore, co-localization of LSD1 with a HMT could result in low levels of H3K4me1/2 but also high levels of H3K4me3 as this mark is protected from LSD1. Pairing HDMs and HMTs with different specificities and/or regulating the enzymatic activities through protein-protein interactions could fine-tune the overall reaction to favor a single methyl state.   Interestingly, loss of H3K4me2 at E2 induced promoters regulated by LSD1 and ER has been previously observed 30. However, this and other studies focused on loss of H3K9me1/2 at hormone-inducible promoters and with good reason given that H3K9 methylation is a well-established repressive mark. The finding that loss of H3K9me1/2 is LSD1-dependent has lead to the conclusion that LSD1 acts as an H3K9me1/2 demethylase directly. We also find LSD1-dependent loss of H3K9me2 at a small number of GR bound 
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sites and GC regulated genes. However, given that only a subset of sites showed changes in H3K9me2 while most showed changes in H3K4me2 we conclude H3K9me2 likely plays a minor or perhaps highly specialized role in regulating GR target genes. We also propose that the LSD1 dependence of H3K9me2 demethylation could be due to interdependence of histone marks, an aspect of the histone code that is very poorly understood in general, let alone in NR-mediated transcriptional regulation. Demonstrating direct enzymatic activity 
in vivo is a significant challenge in enzymatic characterizations, thus in vitro evidence is a mainstay. Contrary to findings with ER and AR, our in vitro characterization of LSD1 enzymatic activity in the GR complex found no evidence of H3K9 demethylation suggesting this activity may be carried out by another HDM. In the case of AR it was proposed that JMJD2C, an H3K9m2/3 and H3K36me2/3 demethylase, and LSD1 cooperated to demethylate H3K9 27. In the GR TAP complex we find JMJD1C, and likely H3K9me1/2 demethylase that has also interacts with AR 82,83. While we do not rule out a role for LSD1 in H3K9 loss in vivo or a contribution by this demethylation event in GC-induced gene activation, we do suggest the mechanistic details are more complex than previously described. The finding that changes in H3K4 methylation, a well-established LSD1 substrate, are part of the activation mechanism and dependent on LSD1 suggests this may be LSD1’s primary role. Also, the observation that both H3K9me2 and H3K4me2 levels track similar increases after TCP treatment (Figures 2.22 A and 2.24) warrants a closer look at potential relationships between H3K4 and H3K9 methylation.   The second role for LSD1 in GR target gene regulation is in suppressing non-specific targets. Expression profiling of DEX responsive genes after LSD1 KD indicates a role for 
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LSD1 in suppressing non-specific targets (Groups E and F, Figure 2.8 B). This combined with our finding that H3K4me2 is enriched at functional GR binding sites and LSD1’s ability to remove H3K4 methylation implicate it in regulating a cell-type specific early poised enhancer code prior to hormone exposure. One plausible mechanism could be that in the absence of GR, LSD1 removes the H3K4me2 (as well as H3K4me1) signature from non-specific enhancers (Figure 2.25 B), while functional sites are protected by some mechanism that preserves the H3K4me2 signal. Upon GC exposure and GR entering the nucleus it binds only those predetermined sites allowing for rapid as well as cell-type specific responses.  This mechanism is reminiscent the original characterization of LSD1 function in the REST complex, where LSD1 is responsible for repressing neuronal genes in non-neuronal cell types 71,84. Similar to the REST complex, LSD1’s role in suppressing non-specific GR targets likely involves multiple other protein regulators responsible for the specificity of distinguishing which sites should and shouldn’t retain H3K4me2. It would be interesting for future studies to identify the HMT and other regulatory factors responsible for laying down the H3K4me2 signature and distinguishing functional from non-functional GR binding sites prior to stimulation. Understanding regulation at this crucial step could lead to important insights into the mechanisms of cell-type specific hormone action.  Our understanding of the histone code often focuses on the offensive side of the equation as we translate the meanings of various histone marks. However, for every histone writer we now understand there is also likely a corollary histone eraser and the balance and targeting 
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of these two activities can almost certainly be tweaked in ways and degrees we don’t yet fully understand.   While LSD1 KD impacts a majority of DEX-responsive genes, it is interesting to note that many were unaffected. Decreasing the stringency for defective activation or repression from 50% to 30% still only brings the number of affected genes to 73%, suggesting there may be mechanistically divergent subsets of GC regulated genes, some relying on LSD1 and others that do not. The wide range in H3K4me2 prior to GR binding (Figure 2.18 A) suggests this mark may also contribute more to the recognition mechanism of some sites than others. Dissecting GC-responsiveness into LSD1-dependent and -independent mechanisms could have important translational implications. The potent anti-inflammatory actions of GCs are limited by significant side effects such as osteoporosis and metabolic disruptions. This has lead researchers to look for selective receptor modulators (SRMs) that can dissociate positive and negative effects 85. However, a molecule with the ability to satisfactorily separate the good from the bad has yet to be discovered. GO analysis of DEX-induced genes showed several known DEX-regulated pathways, such as pro-survival and inflammation. While pro-survival was also a top LSD1-dependent pathway along with proliferation, inflammation dropped out suggesting it was not heavily influenced by LSD1 coactivator function. The GO analysis was supported by cellular assays for DEX and LSD1 affects on apoptosis, proliferation, and IL8 release. While LSD1 was important for DEX-regulation of apoptosis and proliferation, it was not important for DEX-suppression of IL8 mRNA levels or TNFα induced IL8 secretion (Figure 2.13 A and B). While IL8 is not the only point of GC immune regulation and experiments in cell culture do 
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not always predict outcomes at the organism level, our data does support further investigation into the possibility of modulating GC physiological actions through coregulators such as LSD1.   Similarly, the new mechanisms illustrated in this study could also have significant therapeutic implications in the treatment of cancer. The role of GCs in cell proliferation and survival is highly cell type specific. GCs block cell division in lymphoid, fibroblastic, and epithelial tissues 86-88, and induce apoptosis in lymphoid cell lineages such as T-cells and monocytes, contributing to immunosuppression and anti-inflammatory effects, but also their use in treating lymphoid derived cancers 43-45. However, GCs protect from apoptosis in several cell types 46-50, making their use as a co-treatment to reduce nausea and alleviate the acute toxic effects of chemotherapy questionable. For example, concurrent GC and chemotherapy treatment has been shown to inhibit chemotherapy-induced apoptosis in Bcap37 breast cancer 89, HL-60 human leukemia 90, human glioma and rhabdomyosarcoma 
91, human urothelial 92, and human cervical and lung cancer cell lines 93.  Our findings suggest LSD1 inhibitors could be useful in blocking the pro-survival affects of GCs thus assuaging concerns about co-treatment. Additionally, LSD1 inhibitors could potentially sensitize epithelial derived tumors to chemotherapeutic induced apoptosis, adding value to the practice of using GCs in chemotherapy regimes. On the whole we think the nature of LSD1’s role in GR-mediated gene regulation and the importance of GC action both in hormonal regulation of human physiology as well as clinical applications make it a critical coregulator to understand and an appealing therapeutic target. 
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Experimental Procedures 
Cell culture HeLa-s and A549 cells were cultured in DMEM supplemented with 20% FBS. MDA Kb2 cells (ATCC: CRL-2713) were cultured in RPMI 1640 supplemented with 20% FBS. All DEX treatments were carried out after cells were grown in media supplemented with charcoal striped serum for 16-24 hours.  
Proteins, Recombinant protein expression, purification, and GST-pulldown Purified TR, ER, MR (1-110aa), ROR were purchased from Abnova (catalog ID: H00007067-P01, H00002100-P01, H00004306-Q01, H00006096-P01) and AR was purchased from RayBiotech (RB-14-0003P). GST-RAR and RXR was a gift from Dr. Anders Näär. GR and GR truncation mutants were expressed and purified from the pGEX-4T-1 (27-458001) vector in E. coli. The homogeneity of the eluted protein was determined using SDS–PAGE followed by Coomassie blue staining.  For GST pulldown, GR proteins were incubated with 6xHIS-LSD1 overnight at 4°C in buffer containing 200mM NaCl and 0.1% NP-40. 
 
Primers and Antibodies ChIP antibodies were, LSD1 (Abcam ab17721), GR-H300 (Santa Cruz sc-8992), H3K4me1 (Abcam ab8895), H3K4me2 (Millipore 07-030), H3K4me3 (Millipore 07-473), H3K9me2 (Abcam ab1220), H3K27ac (Millipore 17-683), and H3 (Abcam ab1791). The amplification 
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efficiency and specificity of each set of primers was obtained by standard curve analysis and PCR products were separated by 2% agarose gel electrophoresis visualized by ethidium bromide staining.  ChIP-qPCR primer sets BIRC3_TSS GGTTATTACCGCTGGAGTTC   AAATGCGTCACCCAAATCC BIRC3_GRB GATGGCCAGTAATGGAACTG   ATGCATCTCATCAGGGCATC CDKN1C _TSS ACTAGTACTGGGAAGGTCC   TTCTTCTCGCTGTCCTCTC CDKN1C _GRB AGGTCAGCTCACAGGATTG   CCCTTGCGCAAAGAGAAAG DUSP1_TSS GTCAGACCACTTAACTGTGG   GCAAAGGCATGGAAGAGTAG DUSP1_GRB CCAGGTGCATTACAGGTATC   CTTAGGCATGTGACCTTTGG PER1_TSS CATCATGTTCTCTTGGCTGGTGG   AGGACGGCTGTCGTTTTGTTG PER1_GRE CATCAGATTGGAAGTGGCAG   CGACCAGGTAGGCATCTC  
RNA interference, TCP treatments, and RT–PCR Retroviral shRNA (Sigma) targeting human LSD1 (L-sh1:TRCN0000046071, L-sh2:TRCN0000046072) and control scramble (SC) shRNA was used to infect MDA-Kb2 and A549 cells. The knockdown efficiency was determined by RT–PCR and western blot. For all shRNA KD experiments cells were grown in selection media for 5-7 days prior to harvesting. For all TCP experiments cells were also treated for 5-7 days. RNA was purified by Trizol (Life Science) and cDNA produced using SuperScriptIII RT kit (Invitrogen) 
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according to manufacturer’s instructions. Sequences of quantitative RT-PCR primers are available upon request. 
 
Complex purification and  GR-associated protein complexes were purified from HeLa-S cells stably expressing FLAG-HA-GR by sequential anti-FLAG and anti-HA Affinity Gel immunoprecipitation as previously described 94. Cells were treated with 50nM DEX for 6 hours. Associated proteins were sequenced by MS/MS at the Harvard Medical School Taplin Biological Mass Spectrometry Facility. Half of the single FLAG purification or the doubly purified GR complexes, were used for another purification by anti-LSD1 and the associated peptide.   
Microarray A549 cells were infected with retrovirus carrying LSD1 shRNA and selected for 5 days in puromycin prior to treatment with 100nM DEX for 12 hours followed by Trizol (Life Science) RNA extraction. mRNA levels were profiled by Affimetrix 2.0 Microarray chip. 
 
ChIP and ChIP-Sequencing Conventional ChIP was performed as previously described 94 using formaldehyde-crosslinked chromatin with modification to some buffers detailed in supplemental procedures. Briefly, cells were treated with 100nM DEX or ethanol for 2 hours and then cross-linked with 1% formaldehyde for 10 min at room temperature. Cross-linking was stopped by the addition of glycine to 0.125 M. Cells were washed in cold PBS, suspended in buffer (50mM Tris-HCl pH 7.9, 500mM NaCl, 1mM EDTA, 1% Triton-X100, 0.1% Na-
77  
deoxylcholate) and sonicated to obtain DNA fragments with an average size of 500 base pairs. Sonicated chromatin was diluted in half and pre-cleared using IgG, protein A and G beads blocked with BSA/salmon sperm. Incubation with target antibody was carried out overnight at 4°C. Samples were washed twice with sonication buffer, low salt buffer (20mM Tris-HCl pH 8.0, 150mM NaCl, 2mM EDTA, 0.1% SDS, and 1% Triton X-100), high-salt buffer (same as low but with 500mM NaCl) and TE. Eluted, decrosslinked DNA was purified by phenol:chloroform extraction and enrichment of target regions was determined by qPCR (Bio-Rad IQ5) using SYBR Green reagent (Bio-Rad).ChIP-Seq procedure was similar except sonicated fragments were reduced to an average size of 300bp.   ChIP-Seq was carried out following a similar protocol. Purified DNA was used to generate libraries and sequenced by the Illumina Genome Analyzer II (GA II) per manufacturer’s instructions up to 36 cycles. Image analysis and base calling were performed with the Illumina package OLB (v1.8). Sequence reads were mapped onto the reference human genome (NCBI Build UCSC hg19) using the Bowtie (v0.12.7) algorithm. Using the Model based Analysis of ChIP-Seq (MACS) package 95 regions of significant enrichment were determined against sample input. Refseq gene annotation was obtained from the UCSC website. GR peaks were identified using MACS (v1.4) at P<1e-5. Distributions were drawn using in-house software and normalized density. Quantification of LSD1 and H3K4 methyl mark densities for bar graph and ANOVA comparisons were carried out by a density counting program written in-house. Briefly the program generates a density value for a specific DNA region (e.g. the region spanning a GR peak) by calculating the tag enrichment 
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area taking into account signal height and width. Heatmaps were generated using a 100bp window through GR peaks centered ± 2000bp.   
CCK8 proliferation, TUNEL apoptosis, and IL-8 ELISA assays For the CCK8 assays (Dojindo) A549 cells were treated with shRNA against LSD1 (L-sh1 or L-sh2), GR (GR-sh), or LSD2 (L2-sh) and selected for 3 days prior to treatment with either EtOH or various concentrations of DEX for an additional 5 days. Proliferation was detected by CCK8 activity using the BLANK kit according to manufacturer’s instructions.  For TUNEL assays (Roche) A549 cells were treated with shRNA against LSD1 (L-sh1) and selected for 5-7 days prior to fixation and staining according to manufacturer’s instructions. Cells were analyzed by flow cytometry.  For IL8 ELISA assays (Biolegend) A549 cells were treated with shRNA against LSD1 (L-sh1) and selected for 3-4 days prior to plating into 96-well plates. After allowing cells to attach for 24 hours they were treated with DEX for 6 hours followed by a 24 hour treatment with 2ng/ml TNFα. Cells were then washed with PBS and lysed in RIPA buffer for ELISA analysis according to manufacturer’s instructions.   
Histone demethylase assay Histone demethylase assays were carried out as described previously 96. Briefly, 6xHIS-LSD1 was incubated with purified NRs, GR mutants, and/or CoREST for 1h at 4°C prior to overnight incubation at 32°C with bulk histones or purified nucleosomes in demethylase 
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buffer (50mm Tris, pH 8.0, 0.1 Units formaldehyde dehydrogenase (FDH) and 1mM NAD+). In a typical reaction, 4μg of calf thymus histones or 6 μg of purified nucleosomes were incubated with 0.5μg LSD1 and 0.5-2.5μg NR in a total reaction volume of 50μl. Reactions were analyzed by SDS–PAGE and western blotting using methyl-specific antibodies.  
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Abstract The field of histone demethylases has expanded rapidly following the discovery of the first histone lysine demehtylase, LSD1/KDM1A.  New histone modifications are still being discovered along with the enzymes that add and remove these modifications. While the methyltransferases responsible for adding histone methylation have been characterized for all known sites of histone methylation, one site still remains without a characterized demethylase. H3K79 is an interesting site for modification given its location within the globular domain of the histone protein, unlike most modifications occurring on the unstructured tail. While DOT1 is known to methylate H3K79, no demethylase for this residue has been discovered to date. We present evidence here supporting never before characterized H3K79me3 demethylase activity by members of the JMJD2 family of proteins. 
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Background 
HDMs are divided into two major families. One, the flavin-dependent LSD family consisting of 
KDM1A/LSD1 and KDM1B/LSD2, and two, the larger and more diverse Jumonji C (JmjC) 
family consisting of roughly 30 enzymes 1. JmjC HDMs are Fe(II)-dependent hydroxylases that 
utilize the cosubstrates 2-oxoglutarate (2-OG) and molecular oxygen to catalyze demethylation. 
Several subfamilies of JmjC HDMs have been identified and characterized with distinct substrate 
specificities (Table 1.2) 2-9. JmjC HDMs have been implicated in regulating diverse genomic 
processes, such as transcription, cell-cycle progression, heterochromatin maintenance, X 
chromosome inactivation, and development 3,5-7. These functional roles vary among subfamilies 
and are believed to be a consequence of differing histone substrate specificities. 
 
The JMJD2 subfamily is conserved from budding yeast to mammals 3,10-16. Humans have four 
JMJD2 homologs (JMJD2A, JMJD2B, JMJD2C, and JMJD2D), which display dual selectivity in 
removing H3K9me2/3, a mark associated with heterochromatin and gene silencing, and 
H3K36me2/3, a modification demarcating the coding regions of actively transcribed genes 5,16. 
JMJD2 HDMs have been implicated in transcriptional regulation, cell-cycle progression, nuclear 
hormone signaling, embryonic stem cell self-renewal, and development 5-7,17-22. In addition, 
overexpression of several JMJD2 homologs has been linked to cancer 23-25.  
 
While over 30 HDMs have been characterized in the less than 10 years since the discovery of the 
first LSD1, discovery of new HDMs is ongoing. The first histone arginine demethylase, JMJD6, 
was described as recently as 2007 26, opening the field of HDMs beyond lysine residues for the 
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first time. The first H4K20me1 demethylase, PHF8, was only described in 2010 27, leaving 
H4K20me2/3 without a known demethylase. Similarly one of only two methylation site known 
to occur on the histone globular domain, H3K79, has a characterized HMT, DOT1, but to date, 
no known cognate HDM.  
 DOT1 and H3K79 methylation have been implicated in regulating heterochromatin formation 
at telomeres 28 and active transcription. Genome-wide analysis finds that H3K79 methylation is 
enriched in the body of transcribed genes and the amount of methylation is correlated with 
expression level 29. Similar studies in the yeast, fly, and human genomes strongly suggest that 
H3K79 methylation is a marker of active transcription 30-36. The location of H3K79 methylation 
within the gene body along with findings that DOT1 is part of several complexes associated with 
elongating RNA polymerase II implicates this mark in regulating transcriptional elongation 37-39.    DOT1 and H3K79 methylation have also been shown to play an important role in DNA repair. The tandem tudor domain of the 53BP1 protein is able to bind methylated H3K79 and 
this function is required for its recruitment to DNA double-strand breaks 40,41. Because H3K79 
methylation levels do not change after DNA damage, it is thought that double-strand breaks 
change the chromatin structure to expose methylated H3K79, which is then recognized by 53BP1 
40
. DOT1-mediated H3K79 methylation has also been implicated in other forms of DNA repair 
such as nucleotide excision repair (NER), recombination repair (RR), or post-replication repair 
(PRR) and loss of DOT1 results in UV hypersensitivity 42,43. Clearly the role of DOT1 and 
H3K79 methylation is complex and touches multiple important processes from heterochromatin 
formation at telomeres and transcription, to maintaining genome integrity. Each of these roles 
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potentially contributes to the biological functions in development and cardiac function attributed 
to DOT1 thus far 44,45. They also implicate regulation of H3K79 methylation in important human 
diseases such as cancer (reviewed in 46).    
Although the establishment of H3K79 methylation is well characterized and a highly regulated 
processes, active demethylation of this mark is not well understood. However, several lines of 
evidence show dynamaic regulation of this mark therefore suggesting that H3K79 methylation is 
reversible. In yeast and human cells H3K79me2 levels fluctuate throughout the cell cycle 47,48, 
and in both mice and flies H3K79me2 is lost during early embryonic development 49,50. Lastly, a 
study investigating the antagonistic effects of 2-hydroxyglutarate (2-HG) on the JmjC cofactor, 
2-OG, showed a global increase in H3K79me2 suggesting that a dioxygenase such as a JmjC 
enzyme may catalyze the removal of H3K79me2 marks in vivo 51.  Here we show that overexpression of several JMJD2 family HDMs in cell culture results in a global decrease in H3K79me3 levels. Although more is required to fully establish JMJD2A, C, and D as bona fide direct H3K79me3 demethylases, these results support dynamic regulation of H3K79 methylation.  
Results JMJD2 family HDMs have been previously described as H3K36 and H3K9 demethylases. During the course of characterizing a putative HDM, JMJD2C was used as a positive control and found to have a previously uncharacterized activity against H3K79me3. Full-length, HA-tagged JMJD2C was overexpressed in the osteoblast cell line U2OS and 
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immunoflourescence staining against various histone marks were analyzed. A catalytically inactive mutant form of JMJD2C, M-JMJD2C, which disrupts two key amino acids in the iron binding domain (H189A and E191A) was used as a negative control.  A global decrease in H3K79me3 in cells overexpressing wild-type JMJD2C but not the catalytic mutant (M-JMJD2C) was observed (Figure 3.1). Loss of H3K79me3 is specific to the trimethylated state as no decrease in H3K79me2 was observed (Figure 3.2).   Demethylation of H3K36me3, a 
known JMJD2 family substrate, was observed as a positive control (Figure 3.3 A), and as a negative control no demethylation of H3K4me3 was observed (Figure 3.3 B). Quantification of immunoflourescent intensity from histone marks showed that JMJD2C transfected cells 
Figure 3.1  JMJD2C overexpression results in loss of H3K79me3 and is dependent on catalytic HDM activity. HA-tagged, full-length JMJD2C or a catalytically inactive mutant, M-JMJD2C, was overexpressed in U2OS cells for 72 hours prior to immunoflourescent staining against H3K79me3. White dotted circles indicate transected nuclei. Global loss of H3K79me3 is observed in the wild-type JMJD2C transfected cells (top row), but not in the mutant transfected cells (bottom row). 
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have significantly lower levels of H3K79me3 and H3K36me3 with a p-value ≤ 0.001 while JMJD2C-M transfected cells are not significantly different (Figure 3.4). 
 
 Given that the JMJD2 subfamily members share similar substrate specificities, two other members, JMJD2A and JMJD2D, were also tested.  Overexpression of a truncated JMJD2A (1-310aa) containing the catalytic domain, and full-length JMJD2D also caused loss of H3K79me3 in U2OS cells as shown in Figure 3.5. This suggests H3K79me3 may be a substrate for the JMJD2 subfamily of HDMs. Initial experiments with the lung adenocarcenoma cell line, A549, suggests this result is not limited to U2OS cells (data not shown).   
Figure 3.2  JMJD2C overexpression does not result in loss of H3K79me2. HA-tagged, full-length JMJD2C or mutant, M-JMJD2C, was overexpressed in U2OS cells for 72 hours prior to immunoflourescent staining against H3K79me2. White dotted circles indicate transected nuclei. No detectible change in H3K79me2 levels is observed in either the wild-type or mutant transfected cells.  
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Figure 3.3  In addition to of loss of H3K79me3, H3K36me3 is also lost while H3K4me3 is not. HA-tagged, full-length JMJD2C or mutant, M-JMJD2C, was overexpressed in U2OS cells for 72 hours prior to immunoflourescent staining against H3K36me3 (A), or H3K4me3 (B). White dotted circles indicate transected nuclei. Global loss of H3K36me3 is observed in the wild-type JMJD2C transfected cells (top row of A), but not in the mutant transfected cells (bottom row of A). No detectible change in H3K4me3 levels is observed in either the wild-type or mutant transfected cells.  
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Figure 3.4   Quantification of overexpressed JMJD2C activity on H3K79me3 and H3K36me3. Immunoflourescence intensity of histone modifications were quantified in cells expressing either wild-type or mutant JMJD2C and compared to neighboring untransfected cells. JMJD2C transfected cells have significantly lower levels of H3K79me3 and H3K36me3 with a p-value ≤ 0.001 while JMJD2C-M transfected cells are not significantly different. N = 10-20 cells from two separate experiments. 
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Discussion Since the first histone demethylase was discovered in 2004, a number of enzymes have been characterized as histone demethylases acting on specific histone residuals. However, no enzyme has of yet been identified with H3K79 demethylase activity. The evidence presented here suggests that the JMJD2 subfamily of JmjC HDMs may act as H3K79me3 demethylases. The observation that mutating the catalytic domain of JMJD2C abolishes loss of H3K79me3 upon overexpression strongly suggests H3K79me3 levels are regulated by JMJD2C enzymatic activity. While we cannot yet rule out the possibility of indirect regulation via demethylation of other JMJD2 histone substrates, no relationship between 
Figure 3.5   Overexpression of other JMJD2 family members, JMJD2A and JMJD2D, also result in loss of H3K79me3. HA-tagged, truncated JMJD2A (1-310aa) or HA-tagged, full-length JMJD2D was overexpressed in U2OS cells for 72 hours prior to immunoflourescent staining against H3K79me3. White dotted circles indicate transected nuclei. Global loss of H3K79me3 is observed in cells transfected with either construct. 
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H3K36 or H3K9 methylation, two well-established JMJD2 substrates, has been described that could account for the observed H3K79me3 loss. Further in vitro and biochemical characterization with purified JMJD2 proteins will be necessary to convincingly established H3K79me3 as a bona fide substrate.  
One possible explanation for the lag in discovering a H3K79 demethylase may be due to unique 
features related this mark occurring on the globular region of the histone protein rather than the 
tail. Previous studies have shown no activity of JMJD2 HDMs on methylated H3K79 peptides. 
However, characterization of DOTL enzymatic activity shows preferential methylation of 
H3K79 in the context of nucleosomes rather than core histones or recombinant H3 peptide 47, 
suggesting recognition of other features of the nucleosome beyond K79 and adjacent residues. 
This may very well be true for the reverse reaction recognizing and removing H3K79 
methylation, making some of the standard techniques used to characterize novel HDMs 
insensitive to H3K79 demethylase activity.   Interestingly, the substrate specificity of several JMJD2 family members, JMJD2A-D, was recently expanded to include the newly discovered H3K56me3 mark 52. Similar to H3K79, H3K56 is located on the globular core of the histone protein further supporting the possibility that JMJD2 proteins are capable of recognizing and acting on core residues.   H3K79 methylation has been implicated in various cellular processes such as DNA damage repair, cell cycle regulation, transcription and regulation of telomeric heterochromatin 
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formation 40,53,54. It would be interesting to test whether JMJD2A/C/D have roles in these processes via their H3K79me3 HDM activity. 
 
Experimental Procedures U2OS cells were cultured in DMEM supplemented with 20%. For immunoflourescence, cells were fixed with 4% paraformaldehyde and permeabilized with 0.5% triton-X100. After blocking with BSA cells were incubated with the indicated antibody, except H3K79me3, for 2 hours at room temperature. The H3K79me3 antibody (abcam ab2621) was significantly more difficult to stain and therefore incubated for 6-8 hours at room temperature.   M-JMJD2C was generated by site directed mutagenesis of the iron binding site amino acids H189A and E191A. 
 
 
Aknowledgments We thank Johnathan Whetstine for kindly sharing JMJD2A and JMJD2D constructs with us.  
 
 
References  1. Kooistra, S.M. & Helin, K. Molecular mechanisms and potential functions of histone demethylases. Nat Rev Mol Cell Biol 13, 297-311.  2. Allis, C.D. et al. New nomenclature for chromatin-modifying enzymes. Cell 131, 633-6 (2007).  
98  
3. Cloos, P.A., Christensen, J., Agger, K. & Helin, K. Erasing the methyl mark: histone demethylases at the center of cellular differentiation and disease. Genes & development 22, 1115-40 (2008).  4. Krishnan, S., Horowitz, S. & Trievel, R.C. Structure and Function of Histone H3 Lysine 9 Methyltransferases and Demethylases. Chembiochem : a European journal of chemical biology (2011).  5. Mosammaparast, N. & Shi, Y. Reversal of histone methylation: biochemical and molecular mechanisms of histone demethylases. Annual review of biochemistry 79, 155-79 (2010).  6. Nottke, A., Colaiacovo, M.P. & Shi, Y. Developmental roles of the histone lysine demethylases. Development 136, 879-89 (2009).  7. Shi, Y. Histone lysine demethylases: emerging roles in development, physiology and disease. Nature reviews. Genetics 8, 829-33 (2007).  8. Shi, Y. & Whetstine, J.R. Dynamic regulation of histone lysine methylation by demethylases. Molecular cell 25, 1-14 (2007).  9. Upadhyay, A.K., Horton, J.R., Zhang, X. & Cheng, X. Coordinated methyl-lysine erasure: structural and functional linkage of a Jumonji demethylase domain and a reader domain. Current opinion in structural biology 21, 750-60 (2011).  10. Fodor, B.D. et al. Jmjd2b antagonizes H3K9 trimethylation at pericentric heterochromatin in mammalian cells. Genes & development 20, 1557-62 (2006).  11. Katoh, M. Identification and characterization of JMJD2 family genes in silico. International journal of oncology 24, 1623-8 (2004).  12. Kim, T. & Buratowski, S. Two Saccharomyces cerevisiae JmjC domain proteins demethylate histone H3 Lys36 in transcribed regions to promote elongation. The Journal of biological chemistry 282, 20827-35 (2007).  13. Klose, R.J. et al. The transcriptional repressor JHDM3A demethylates trimethyl histone H3 lysine 9 and lysine 36. Nature 442, 312-6 (2006).  14. Klose, R.J. et al. Demethylation of histone H3K36 and H3K9 by Rph1: a vestige of an H3K9 methylation system in Saccharomyces cerevisiae? Molecular and cellular biology 27, 3951-61 (2007).  15. Tu, S. et al. Identification of histone demethylases in Saccharomyces cerevisiae. The Journal of biological chemistry 282, 14262-71 (2007).  
99  
16. Whetstine, J.R. et al. Reversal of histone lysine trimethylation by the JMJD2 family of histone demethylases. Cell 125, 467-81 (2006).  17. Black, J.C. et al. Conserved antagonism between JMJD2A/KDM4A and HP1gamma during cell cycle progression. Molecular cell 40, 736-48 (2010).  18. Iwamori, N., Zhao, M., Meistrich, M.L. & Matzuk, M.M. The testis-enriched histone demethylase, KDM4D, regulates methylation of histone H3 lysine 9 during spermatogenesis in the mouse but is dispensable for fertility. Biology of reproduction 84, 1225-34 (2011).  19. Lin, C.H. et al. Heterochromatin protein 1a stimulates histone H3 lysine 36 demethylation by the Drosophila KDM4A demethylase. Molecular cell 32, 696-706 (2008).  20. Loh, Y.H., Zhang, W., Chen, X., George, J. & Ng, H.H. Jmjd1a and Jmjd2c histone H3 Lys 9 demethylases regulate self-renewal in embryonic stem cells. Genes & development 21, 2545-57 (2007).  21. Lorbeck, M.T. et al. The histone demethylase Dmel\Kdm4A controls genes required for life span and male-specific sex determination in Drosophila. Gene 450, 8-17 (2010).  22. Strobl-Mazzulla, P.H., Sauka-Spengler, T. & Bronner-Fraser, M. Histone demethylase JmjD2A regulates neural crest specification. Developmental cell 19, 460-8 (2010). 23. Shin, S. & Janknecht, R. Activation of androgen receptor by histone demethylases JMJD2A and JMJD2D. Biochemical and biophysical research communications 359, 742-6 (2007).  24. Wissmann, M. et al. Cooperative demethylation by JMJD2C and LSD1 promotes androgen receptor-dependent gene expression. Nature cell biology 9, 347-53 (2007).  25. Kim, T.D., Oh, S., Shin, S. & Janknecht, R. Regulation of tumor suppressor p53 and HCT116 cell physiology by histone demethylase JMJD2D/KDM4D. PloS one 7, e34618 (2012).  26. Chang, B., Chen, Y., Zhao, Y. & Bruick, R.K. JMJD6 is a histone arginine demethylase. Science 318, 444-7 (2007).  27. Qi, H.H. et al. Histone H4K20/H3K9 demethylase PHF8 regulates zebrafish brain and craniofacial development. Nature 466, 503-7.  28. Norris, A. & Boeke, J.D. Silent information regulator 3: the Goldilocks of the silencing complex. Genes & development 24, 115-22 (2010).  
100  
29. Steger, D.J. et al. DOT1L/KMT4 recruitment and H3K79 methylation are ubiquitously coupled with gene transcription in mammalian cells. Molecular and cellular biology 28, 2825-39 (2008).  30. Pokholok, D.K. et al. Genome-wide map of nucleosome acetylation and methylation in yeast. Cell 122, 517-27 (2005).  31. Ng, H.H., Ciccone, D.N., Morshead, K.B., Oettinger, M.A. & Struhl, K. Lysine-79 of histone H3 is hypomethylated at silenced loci in yeast and mammalian cells: a potential mechanism for position-effect variegation. Proceedings of the National Academy of Sciences of the United States of America 100, 1820-5 (2003).  32. Schubeler, D. et al. The histone modification pattern of active genes revealed through genome-wide chromatin analysis of a higher eukaryote. Genes & development 18, 1263-71 (2004).  33. Okada, Y. et al. hDOT1L links histone methylation to leukemogenesis. Cell 121, 167-78 (2005).  34. Okada, Y. et al. Leukaemic transformation by CALM-AF10 involves upregulation of Hoxa5 by hDOT1L. Nature cell biology 8, 1017-24 (2006). 35. Vakoc, C.R., Sachdeva, M.M., Wang, H. & Blobel, G.A. Profile of histone lysine methylation across transcribed mammalian chromatin. Molecular and cellular biology 26, 9185-95 (2006).  36. Wang, Z. et al. Combinatorial patterns of histone acetylations and methylations in the human genome. Nature genetics 40, 897-903 (2008).  37. Krogan, N.J. et al. The Paf1 complex is required for histone H3 methylation by COMPASS and Dot1p: linking transcriptional elongation to histone methylation. Molecular cell 11, 721-9 (2003).  38. Mueller, D. et al. Misguided transcriptional elongation causes mixed lineage leukemia. PLoS biology 7, e1000249 (2009).  39. Bitoun, E., Oliver, P.L. & Davies, K.E. The mixed-lineage leukemia fusion partner AF4 stimulates RNA polymerase II transcriptional elongation and mediates coordinated chromatin remodeling. Human molecular genetics 16, 92-106 (2007).  40. Huyen, Y. et al. Methylated lysine 79 of histone H3 targets 53BP1 to DNA double-strand breaks. Nature 432, 406-11 (2004).  41. Wysocki, R. et al. Role of Dot1-dependent histone H3 methylation in G1 and S phase DNA damage checkpoint functions of Rad9. Molecular and cellular biology 25, 8430-43 (2005).  
101  
42. Bostelman, L.J., Keller, A.M., Albrecht, A.M., Arat, A. & Thompson, J.S. Methylation of histone H3 lysine-79 by Dot1p plays multiple roles in the response to UV damage in Saccharomyces cerevisiae. DNA repair 6, 383-95 (2007).  43. Lazzaro, F. et al. Histone methyltransferase Dot1 and Rad9 inhibit single-stranded DNA accumulation at DSBs and uncapped telomeres. The EMBO journal 27, 1502-12 (2008).  44. Nguyen, A.T. et al. DOT1L regulates dystrophin expression and is critical for cardiac function. Genes Dev 25, 263-74.  45. Jones, B. et al. The histone H3K79 methyltransferase Dot1L is essential for mammalian development and heterochromatin structure. PLoS Genet 4, e1000190 (2008).  46. Nguyen, A.T. & Zhang, Y. The diverse functions of Dot1 and H3K79 methylation. Genes & development 25, 1345-58 (2011).  47. Feng, Q. et al. Methylation of H3-lysine 79 is mediated by a new family of HMTases without a SET domain. Current biology : CB 12, 1052-8 (2002). 48. Schulze, J.M. et al. Linking cell cycle to histone modifications: SBF and H2B monoubiquitination machinery and cell-cycle regulation of H3K79 dimethylation. Molecular cell 35, 626-41 (2009).  49. Shanower, G.A. et al. Characterization of the grappa gene, the Drosophila histone H3 lysine 79 methyltransferase. Genetics 169, 173-84 (2005).  50. Ooga, M. et al. Changes in H3K79 methylation during preimplantation development in mice. Biology of reproduction 78, 413-24 (2008).  51. Xu, W. et al. Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of alpha-ketoglutarate-dependent dioxygenases. Cancer cell 19, 17-30 (2011).  52. Jack, A.P. et al. H3K56me3 is a novel, conserved heterochromatic mark that largely but not completely overlaps with H3K9me3 in both regulation and localization. PloS one 8, e51765 (2013).  53. Schulze, J.M. et al. Linking cell cycle to histone modifications: SBF and H2B monoubiquitination machinery and cell-cycle regulation of H3K79 dimethylation. Mol Cell 35, 626-41 (2009).  54. Steger, D.J. et al. DOT1L/KMT4 recruitment and H3K79 methylation are ubiquitously coupled with gene transcription in mammalian cells. Mol Cell Biol 28, 2825-39 (2008).  
102  
Appendix A _________________________________________________________________________________________________  
 
103   
104  
105  
106  
107  
108  
109  
110  
111  
112  
113  
114  
115  
Appendix B ________________________________________________________________________________________________
116  
117  
118  
119  
120  
121  
122  
123  
124  
125  
126  
127  
128   
